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CHAPTER 1 
Introduction 
Since the classic experiments of Tigerstedt and Bergman (!) in 1898, in which a 
pressor substance, renin, was discovered in rabbit kidney extracts, and since the 
discovery in 1934 by Goldblatt and co-workers (2) that renal artery constriction 
caused hypertension in the dog, evidence for involvement.of renin in the pathogenesis 
of various forms of clinical and experimental hypertension has been collected by 
many investigators (3-8). Renin itself has no effect on arterial pressure but acts 
through the formation of the vasopressor peptide, angiotensin II. In many respects this 
renin-angiotensin system resembles the kallikrein-kinin system, by which the vasodi-
lator peptides, kallikrein and bradykinin, are formed. Indeed, in recent years, the 
kallikrein-kinin system has also been implicated in the regulation of blood pressure (9, 
10). 
Features of the two systems that are relevant to the pathogenesis of hypertension and 
to pharmacological modulation of their actions will be described in this chapter. 
1.1. Renin-angiotensin system 
Renin substrate, angiotensinogen, in plasma is produced by the liver. It is cleaved by 
a proteolytic enzyme, renin, liberating a decapeptide, angiotensin I (Fig. 1). Renin is 
produced in the juxtaglomerular cells of the kidney. Substances with renin-like acti-
vity have been described in uterus, placenta, brain, adrenal gland, submaxillary gland 
and in large arteries and veins. Recent experiments suggest that renin is produced as 
an inactive precursor form that is activated before and, possibly, also after its release 
into the circulation (11, 12). Angiotensin I, which has no biological activity, is subse-
quently cleaved by a dipeptidyl-carboxypeptidase, angiotensin-converting enzyme, to 
form the octapeptide, angiotensin II. Plasma levels of converting enzyme are relatively 
low but very high concentrations of the enzyme have been demonstrated in the 
vascular endothelial cells of the lung. More recently angiotensin-converting enzyme 
activity has also been demonstrated in brain, heart, kidney and lymph (13). Angioten-
sin II, which is formed by removal of the C-terminal histidyl-leucine group of angio-
tensin I, is a very potent vasoconstrictor. It also stimulates the adrenal cortex to 
secrete aldosterone (3) and it facilitates adrenergic neurotransmission (14). Angioten-
sin II can subsequently be converted into the heptapeptide, angiotensin Ill, which, in 
some species, stimulates the adrenal cortex to produce aldosterone and has also been 
shown to have angiotensin ll-like effects on the renal circulation (15). Both angioten-
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sin II and angiotensin Ill are finally degraded by angiotensinases into biologically 
inactive fragments. 
1.2. Kallikrein-kinin system 
Kinins are liberated from specific alpha2-globulins, kininogens, by proteolytic enzy-
mes called kallikreins (9, 10). Kininogens are present in two forms, high molecular 
weight kininogen and low molecular weight kininogen. Kallikreins have been divided 
into two classes, those derived from plasma and those produced by glands. Glandular 
kallikrein forms kallidin (lys-bradykinin), a decapeptide, from both high and low 
molecular weight kininogen. Plasma kallikrein forms bradykinin, a nona peptide. from 
high molecular weight kininogen. The kinins are very potent vasodilators. Bradykinin 
has also been shown to be a potent stimulant of phospholipase A2; it augments the 
availability of arachidonic acid for prostaglandin synthesis (16). Bradykinin and kal-
lidin are inactivated by circulating and local kininases. Two kininases have been 
isolated from plasma, kininase I and II. Kininase II appears to be more prominent in 
tissue and has been shown to be identical to angiotensin-converting enzyme (13) (Fig. 
2). 
RENIN SUBSTRATE 
• Asp-Arg· Val-Tyr-11 eu-H is-Pro-Phe·H is-Leu-Leu-Voi-Tyr-Ser-R 
f 
ANGIOTENSIN I 
• Asp-Arg-Val-Tyr-lleu-H is-Pro-Phe-H is-Leu 
f 
ANGIOTENSIN II 
Asp+Arg-Val-Tyr-lleu-H is-Pro-Ph e 
f 
ANGIOTENSIN Ill 
t + Arg-Vai-Tyr-lleu-H is-Pro-Phe 
INACTIVE FRAGMENTS 
Figure I. Renin-angiotensin system 
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1.3. Pharmacological modulation of the renin-angiotensin and kallikrein-kinin 
systems 
Pharmacological modulation of the renin-angiotensin system is now possible at 
various steps in the system both as a research tool to establish the role of renin and 
angiotensin in different forms of hypertension and as a therapy in various clinical 
conditions (7,8). Although the concentration of renin substrate in plasma can be 
altered by drugs, there are little data on the physiological effects of such changes. The 
level of active renin in plasma can be influenced in various ways. Renin can be 
inhibited by substances, like pepstatin, but these are rather toxic and cannot be used in 
humans. Currently less toxic renin inhibitors are being tested (17 a-c). The method 
most commonly used to lower plasma active renin is by beta-adrenoceptor blocking 
agents, such as propranolol (3,8). These drugs, however, also have a profound effect 
on the sympathetic nervous system (19) and it is therefore difficult to determine 
which part of their blood pressure lowering effect is due to inhibition of the renin-
angiotensin system. Another way to block the renin-angiotensin system is by the use 
of competitive inhibitors of its most important biologically active end-product, angio-
tensin II. Various analogues of angiotensin II have been studied, of which sar1-ala8-
angiotensin II (Saralasin) is most widely used (20). However, its partial agonistic 
effect has limited its use as a research tool. These analogues are only active when given 
intravenously and they are short-acting, thereby limiting their use in clinical practice. 
More recently a new approach to the renin~angiotensin system has become available 
by the discovery of specific inhibitors of angiotensin-converting enzyme. These were 
isolated from the venom of a viper, Bothrops Jararaca (2!). Of these compounds the 
nonapeptide Teprotide (<Glu-Trp-Pro-Arg-Pro-Gln-lle-Pro-Pro) has been studied 
most extensively. The drug is a very effective inhibitor of angiotensin-converting 
enzyme both in vitro and in vivo. It lowers blood pressure in hypertensive patients 
(22). The question can be raised whether this fall in blood pressure is really caused by 
blockade of the renin-angiotensin system. Theoretically, inhibition of angiotensin-
converting enzyme, which is identical to kininase II, in the intact organism may not 
only lead to diminished angiotensin II production but also to bradykinin accumula-
tion (23). Teprotide has to be administered parenterally. The finding that this agent 
lowers blood pressure in most hypertensive patients has provided the impetus for the 
development of orally active inhibitors of angiotensin-converting enzyme. Unlike 
most other antihypertensive drugs these inhibitors were the result of a rational drug 
design based on postulated molecular similarities between angiotensin-converting 
enzyme and other characterized carboxypeptidase enzymes (24 ). In 1973 it was repor-
ted that D-2-benzylsuccinic acid was an inhibitor of pancreatic carboxypeptidase A. 
·presumably because of the interaction of the inhibitor molecule with three binding 
sites in the enzyme. This observation along with the apparent similarities between 
carboxypeptidase A and angiotensin-converting enzyme and the knowledge that all 
known venom angiotensin-converting enzyme inhibitors contain two proline residues 
in their C-terminal portion have led to the synthesis of a series of compounds that are 
potent and specific inhibitors of angiotensin-converting enzyme both in vitro and in 
vivo. Of these 2-D-3-mercapto 2-methylpropanoyl-L-proline (SQ 14225 or capto-
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figure 2. Renin-angiotensin and kallikrein-kinin systems. The central role of converting enzyme. 
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Figure 3. Proposed binding of captopril to the active site of angiotensin-converting enzyme. 
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pril) was selected as the optimal compound for clinical trials (Fig. 3). 
Shortly after the introduction of captopril preliminary studies on the efficacy of the 
drug showed rather conflicting results. Some investigators demonstrated a very strong 
correlation between the acute fall of blood pressure, 60-90 minutes after the first oral 
dose of captopril, and the pretreatment levels of active plasma renin (25,26), whereas 
others were not able to find such correlation (27). Conflicting results have also been 
reported with respect to the chronic effect of captopril (25,26,28,29). Some authors 
have further reported that the chronic effect on blood pressure could still be demon-
strated despite the fact that their measurements of converting enzyme in plasma 
seemed to indicate that the enzyme was not blocked during part of the day (30). In a 
small uncontrolled study in patients with various forms of hypertension Cody et al 
(3!) showed that captopril acted as an arteriolar and venous vasodilator but from this 
study no conclusions can be drawn as to the influence of the pretreatment activity of 
the renin-angiotensin system on these haemodynamic responses. Although it has been 
shown that aldosterone falls after captopril, conflicting data have been reported on 
fluid balance during the first week of treatment with captopril (32). There is also little 
information on the more long-term effects of captopril on the renal circulation and 
body fluid volumes. Some authors have demonstrated an improvement of renal func-
tion during acute treatment with captopril (33) but deterioration of renal function has 
also been reported (34). 
1.4. Aim of the study 
The aim of the study presented in this thesis was to clarify firstly whether or not 
pretreatment plasma renin is an important predictor of the blood pressure response to 
captopril during both acute and chronic treatment and to establish in more detail the 
haemodynamic profile of actions of this drug in various forms of hypertension. For 
this purpose the effects of captopril treatment were investigated in patients with a 
wide range of plasma levels of renin i.e. normotensive anephric patients in whom 
active renin in plasma was almost zero, patients with essential hypertension with low 
to normal renin and patients with renovascular hypertension with normal to high 
renin and finally in normotensive patients with heart failure with renin levels that 
were often extremely high. A second goal of the present study was to provide some 
insight into the relation between the degree of inhibition of converting enzyme with 
captopril and the antihypertensive effect of this drug. Finally, some data were collec-
ted on the acute and chronic effects of captopril on renal function in essential and 
renovascular hypertension. 
Chapter 2 gives a description of the methods we have used. Chapter 3 deals with the 
effects of captopril on haemodynamic parameters and body fluid volumes in mild to 
moderate essential and renovascular hypertension and in severe, so-called drugresis-
tant, hypertension. Chapter 4 presents further data on the haemodynamic effects of 
captopril in essential and renovascular hypertension as well as in cardiac failure. The 
results are related to the pretreatment levels of plasma renin. Chapter 5 describes the 
effect of captopril on blood pressure in nephrectomized patients. In chapter 6 a 
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comparison is made between the acute effects of captopril on blood presure in reno-
vascular and essential hypertension and in anephric normotensive patients. Chapter 7 
deals with the measurement of converting enzyme in plasma in patients on captopril. 
The results of this measurement are related to the blood pressure response to this drug. 
Chapter 8 describes the effects of captopril on renal function in patients with renovas-
cular hypertension. Chapter 9 describes the renal effects of captopril in patients with 
essential hypertension. In chapter 10 the conclusions to be drawn from our studies 3.re 
discussed. 
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CHAPTER2 
Methods 
2.1. Arterial pressure and heart rate 
Arterial pressure in the acute studies was measured intra-arterially through a catheter 
in either the radial or brachial artery. The catheter was connected with a pressure 
transducer (P231D Gould-Statham) and a monitor with digital display (Hewlett-
Packard 78205 C). In the chronic studies the London School of Hygiene sphygmoma-
nometer (MK4) was used in order to minimize observer bias (I). Three consecutive 
pressure readings were averaged. Disappearence of Korotkoff sounds (phase V) was 
taken as diastolic pressure. Mean arterial pressure was calculated from cuff pressure 
readings as diastolic pressure + 1/3 x pulse pressure. Heart rate was calculated from a 
continuous ECG-recording. 
2.2 Cardiac output 
The methods for measuring cardiac output used in our studies are based on the 
principle of indicator dilution as described by Steward and Hamilton (2_3). The dye 
dilution technique is generally accepted as a standard procedure. This technique, 
however, is not suitable for repeated measurements within a short period of time 
because there is a limit to the amount of dye that can be injected. Moreover, this 
method is not suitable for repeated measurements over periods of weeks or months 
because it requires arterial cannulation. 
Thermodilution method. In acute studies cardiac output was determined by triple-
lumen thermal dilution Swan-Ganz catheter (model 93A-131-7F, Edwards Laborato-
ries Inc.). This catheter was introduced under local anaesthesia by a modified Sel-
dinger technique via an antecubital vein. The catheter tip was placed in a major 
segment of the pulmonary arterial bed, so that pulmonary arterial pressure and pul-
monary wedge pressure could be recorded. Right atrial pressure was also measured at 
frequent intervals. Cardiac output was determined from three consecutive thermodilu-
tion curves. Ten ml of glucose solution (0.28 mol/1) at 0°C was used. The indicator 
solution was injected manually over less than three seconds. Incomplete or delayed 
injections were discarded. Dilution curves were recorded and cardiac output was 
calculated by a computer (Model no 9520, Edwards Laboratories Inc, California, 
USA). 
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Isotope dilution method. In the chronic studies cardiac output was measured by the use 
of an isotope dilution method (4-11). 99mTechnetium pertechnetate from a 
99Mo -99 mTc generator (New England Nuclear) was used as an indicator. The 
99mTechnetium pertechnetate was bound to human serum albumin (20% in 0.15 moll! 
NaCl) by electrolytic complexation according to Benjamin et al (12), as modified by 
Dworkin and Guttowski (13). 
Cardiac output was measured with 100-200 f.'Ci (3.7-7.4 MBq) 99mTc-albumin in 0.2 
ml 0.15 moll! NaCl. The isotope was injected via a small intravenous catheter with a 
dead space of0.6 ml. The tracer bolus was flushed into the circulation with 10 ml 0.15 
moll! NaCl. The volume of tracer injected was determined by weighting the syringe 
before and after injection. The radioactivity of the preparation injected was measured 
in a well~type scintillation counter. 
count 
rotc 
···················~.······ =[) ~fi1·.········· 
Figure 1. Recording of a radiocardiogram. PMT: photomultiplier tube. Shaded area represents first circula-
tion of the isotope. Rf: reference value of blood radioactivity in the equilibrium phase as measured over the 
heart. 
The detection device consisted of a thallium-activated sodium-iodine crystal of 5 x 5 
em, mounted on a photomultiplier tube (Philips-XL-7007/10). Collimation was 
effected' by means of a conical lead collimator, wall thickness 2 em, inner aperture 4.5 
em, outer aperture 6.7 em, depth 8,1 em (Philips-XL-6011101). The detector was 
used in conjunction with a power supply and rate-meter (Philips-XL-1100), with a 
time constant of 0.4 seconds. A conventional pen recorder (Philips-PM 8010) with a 
chart speed of25 em per minute was used (full scale deflection 25 em in 0.8 seconds). 
Recordings were made during 60 seconds after injection of the tracer, and again after 
five min and 10 min, when blood samples were taken for determination of plasma 
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radioactivity. The detector was placed over the fourth left intercostal space, with its 
centre over the left sternal margin. In this way curve recordings were obtained in all 
patients with accentuation of the right ventricle peak of the radiocardiogram. In this 
way the contribution of the area under the extrapolated part of the curve to the total 
area was reduced, while the length of the left ventricular downslope was still sufficient 
for accurate extrapolation. 
Cardiac output (CO) was calculated from the equation: 
. dose injected (cpm) x paper speed (em/min) x Rf (em) x I0-3 
CO (L/mm)= plasma radioactivity (cpm/ml) x area (cm2) x (1-Hct) 
Rfrepresents the deflection oft he pen recorder in centimetres as a reference value for 
blood radioactivity in the equilibrium phase after five and 10 min. The plasma 
radioactivity after five and 10 min was measured in a well-type scintillation counter 
and converted into blood radioactivity by correcting for haematocrit (Hct). The area 
under the curve during the first phase was determined with a planimeter. To extrapo-
late the left ventricular downslope. it was transformed on semilogarithmic paper with 
linear extrapolation. The extrapolated values were than replotted on the original 
tracing. The arithmatic mean of the cardiac output values derived from the five and 10 
min registration was calculated. 
2.3. Validation of the isotope-dilution cardiac output measurement 
Distribution volume of 99 mTc-albumin. For the isotope method of cardiac output 
measurement to be valid the tracer should remain in the circulation during the first 
passage through the he:ut. This could be proved by comparing the in vivo distribution 
volume of 99mTc~albumin with the distribution volume of 1311-albumin (5 ,uCi, 0.2 
MBq) in 15 patients and of 113 ln-transferrin (200 ,uCi. 7.4 MBq) in 25 patients 
(14-16). Oedematous patients were not included. The distribution volumes of 131 1-
albumin and 113Jn-transferrin are known to correspond with plasma volume. Blood 
samples were taken from the recumbent patients 0. 5, 10, 20, 30 and 40 minutes after 
injection of the tracer. Plasma radioactivity was determined in a well-type scintilla-
tion counter. Decrease of radioactivity with time was extrapolated to time zero for 
calculation of distribution volume. Loss of tracer from the circulation was less than 10 
percent during the 40 min time of plasma volume measurement. Figure 2 represents 
the values of the 99 mTc-albumin measurements versus 131!-albumin and 113In-
transferrin measurements (n= 15, r=0.94 and n=25, r=0.97 respectively). No sys-
tematic difference was found between the distribution of the two tracers. Free radioac-
tivity, as determined by trichloroacetic acid precipitation of the 99 mTc-albumin 
preparation (17), was 2.0±0.15% (mean±SEM. n=54). 
Comparison with dye dilution. The correlation between the radioactive method and the 
indocyanine green dilution method was studied in 30 patients (n=57). In these 
patients "mTc-albumin was flushed into the circulation simultaneously with 1 ml 
solvent containing 5 mg Cardiogreen. Cardiac output was measured using a Gilford 
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Figure 2. Correlation of distribution volumes of qqmTc-HSA versus 13 11-HSA {n=IS. r=0.94) and 
q~mTc-HSA versus 113 mln-Transferrin (n=25, r=0.97). HSA=human serum albumin. 
cardiac output system (model 140. Gilford Instrument Laboratories Inc, Oberlin, 
Ohio, USA). which is equipped with a dynamic calibration device and a small digital 
computer. Time concentration curves were recorded from blood drawn from a 
brachial artery. In II patients both indicators were injected simultaneously directly 
into the right atrium. In the remaining patients the tracers were injected into an 
antecubital vein. 
Figure 3 compares the results of cardiac output measurements by the isotope and dye 
dilution methods after central injection (n= II, r=0.99). After injection into an 
antecubital vein in 30 patients (n=57) an r-value of 0.92 was obtained (Fig. 4). 
Values measured by isotope dilution were systematically higher than dye dilution 
values. Factors contributing to this systematic difference are the wide-angle type of 
collimator and the type of isotope. The gamma radiation of 99 mTc has a low energy, 
thereby raising the relative contribution of extracardial radioactivity in the equi-
librium phase so that Rf is overestimated. The mean of the individual dye cardiac 
output/isotope cardiac output ratios was 0.75 and this factor was used for correction 
of isotope cardiac output values. 
In 38 duplicate measurements (Fig. 5) the coefficient of variation was 6%. There was 
no statistical difference between the first and second determination (p>0.05, Stu-
dent's Hest). 
The influence of extreme positioning of the detector over the right and left side of the 
heart is shown in Fig. 6. Even in these extreme positions a reasonable correlation was 
found (n = 18, r=0.82). Our results indicate that small variations in the position of the 
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detector over the heart during follow-up studies in individual patients are of minor 
importance. 
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Figure 3. Correlation between cardiac output values obtained by isotope dilution (Tc) and dye dilution 
(Dye), after central injection of the indicators (n= I I. r=0.99) 
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Figure 5. Duplicate measurements of cardiac output by isotope dilution (n=38. r=0.96). Dotted line 
represents line of identity. Drawn line is line of regression. 
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Figure 6. Cardiac output measurements by isotope dilution with the detector in extreine left and right 
positions over the heart (n=IS. r=0.82). Dotted line represents line of identity. 
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2.4. Total renal function 
Renal plasma flow and glomerular filtration rate were measured by clearance studies. 
When a substance is excreted exclusively by means of glomerular ultrafiltration, the 
clearance of this substance is equal to glomerular filtration rate. When a subst'ance is 
completely and exclusively removed from plasma during one single passage through 
the kidney, the clearance of this substance is equal to renal plasma flow. The clearance 
of a substance, X. can be calculated by the standard formula: 
C x = ,::Uccx,__·_V-'-"c 
· Px 
in which: 
Cx = clearance of X expressed as ml!min 
Ux =concentration of X in urine (mmollmin) 
V c =volume of urine (mllmin) 
Px = plasma concentration of X (mmol/min) 
The major problem with this type of measurement is the requirement of correct urine 
collection. However, when a substance, which is neither formed nor metabolized in 
the body and which is excreted solely by the kidney, is infused at a constant rate 
sufficient to keep plasma levels constant, U x • V u can be substituted by the amount of 
substance infused per minute (18-20). The formula then becomes: 
_lx. VI Cx---
. Px 
in which: 
lx = concentration of X in the infusion fluid (mmollmin) 
V1 = infusion rate (mllmin) 
To reach a constant plasma concentration it is necessary that the substance is 
uniformly distributed in plasma within a short period of time. This can be achieved by 
administering a priming dose, which is then followed by a constant infusion of a lower 
dose of the substance. 1' 11-sodium iodohippurate (hippuran) was used as a marker for 
measuring renal plasma flow and 1251-thalamate was used as a marker for measuring 
glomerular filtration rate. Combined infusion of the two substances was used for 
measuring renal plasma flow and glomerular filtration rate at the same time (21,22). 
The sustaining solution contained 200 ,uCi (7.4 MBq) 1'1!-hippuran and 50 ,uCi (!.8 
MBq) 1251-thalamate (Radiochemical centre, Amersham, UK) in 100 ml 0.15 moll! 
NaCl. After at least two hours of supine rest a plasma blank sample was drawn from 
an indwelling teflon cannula in an antecubital vein. Then, a priming dose of 0.15-0.20 
ml per kg body weight of the sustaining solution was infused by the use of an infusion 
pump at a rate of I mllmin. The infusion rate was then switched to 0.1 mllmin. In 
this way constant plasma levels of 1' 11-hippuran and 1"I-thalamate were obtained 
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60-90 minutes after the start of the infusion (22). Blood samples were drawn at 60, 90, 
120. 150, !80 and 210 minutes. Separation of plasma was performed immediately 
after collection of the blood samples. In 2 ml plasma and diluted (11100) sustaining 
solution the activities of 131 1-hippuran and 1251-thalamate were determined in a well-
type gamma scintillation counter and the measured 1251-values were corrected for the 
contribution of 131 1-hippuran in the 1251-window by measuring a pure I3IJ-hippuran 
sample. There was no detectable contribution of 1251 in the 13 lf-window. Clearances 
were calculated from the 90-, 120-, 150-,!80- and 2!0-min samples. The values were 
averaged. Because renal extraction of 1311-hippuran was not complete during one 
single passage through the kidney, the value for renal plasma flow we have found was 
falsely low and was therefore considered to reflect the so-called effective renal plasma 
flow. In a series of 25 patients with uncomplicated essential hypertension this extrac-
tion ratio appeared to be 75.! ± 1.0%. and by correcting for this, true renal plasma 
flow can be calculated. Renal blood flow is calculated by correcting for haematocrit 
(22). 
2.5. Split renal function 
For measuring the renal extraction ratio of 131 1-hippuran and of 1251-thalamate blood 
samples were taken simultaneously from the aorta and the renal vein on each side. 
Single-kidney extraction ratio (extraction efficiency) was calculated as 100 (A-V)/ A, 
where A = activity in abdominal aorta and V = activity in renal vein. 
The single-kidney uptake of 99mTc-diethylenetriaminepenta-acetic acid C9mTc-
DTPA) was determined by scintillation camera renography. Approximately 5-10 mCi 
(185-370 MBq) 99mTc-DTPA was injected intravenously. Lightpen 'regions of inte-
rest" corresponding to the left and right kidneys were traced on the display screen 
using the 3-min summation image. Time-activity curves of each kidney region were 
displayed. Counting rates from the kidney areas were corrected for background acti-
vity using a region of interest between the kidneys. Single-kidney function was estim-
ated from the radioactivity over the kidney regions 60-120 seconds after injection and 
expressed as activity ratio, that is right/(right+left). This ratio is a measure of the 
single-kidney's contribution to total glomerular filtration rate (23-24). 
2.6. Extracellular fluid volume and plasma volume 
Sulphate space was measured as an estimate of extracellular fluid volume (25,26) by 
intravenous injection of 3-4 ml of a solution ofNa,''SO, in 0.15 moll! NaCl (2.5-3.0 
1-'Ci/ml, 0.09-0.11 MBq/ml). The tracer was flushed into the circulation with 10 ml, 
0.15 mol/! NaCI. The volume of tracer injected was determined by weighting the 
syringe before and after injection. At 30, 60, 80, 100, 120, and 140 minutes, blood 
samples were drawn. Plasma samples of I ml were counted in a liquid scintillation 
counter. After correction for quencing and background by the use of a plasma blank 
and an internal standard the results were plotted against time on semilogarithmic 
paper. For extrapolation to time zero the samples from 60-140 minutes were used and 
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sulphate space (extracellular fluid volume, ECV) was calculated according to the 
formula: 
ECV (L) = plasma counts at time zero (cpm/ml) 
dose injected (cpm) X 103 
No correction was made for the Donnan equilibrium between plasma and interstitial 
fluid, 'dry' plasma constituents and sulphate loss in the urine. 
Plasma volume was estimated by the use of 99mTc-labeled human serum albumin at 
the time of cardiac output measurement, as described before. 
2.7. Chemical assays 
Angiotensin-converting enzyme. Angiotensin-converting enzyme in plasma was mea-
sured by a spectrophotometric assay based on the methods of Cushman and Cheung 
(27) and Le Treut et al (28). Peripheral venous blood was collected in tubes contai-
ning lithium heparin as the anticoagulant. Plasma was prepared by centrifugation at 
4°C, immediately after blood sampling. A 50-1!1 portion of plasma was added to 200 
!' l of a freshly prepared solution of the substrate hippuryl-L-histidyl-L-leucine 
(Sigma Chemical Co, St.Louis, USA) in borate/NaCl buffer. The substrate solution 
contained the following components: hippuryl-L-histidyl-L-leucine (6.25 mmolll), 
sodium borate (0.125 moll!) and NaCl (0.375 moll!): pH was adjusted to 8.3. The 
substrate/plasma mixture was incubated at 37°C in a shaking water bath for one hour. 
The reaction was stopped with 250 !'1 of HCl (l moll!). A blank was prepared by 
adding the acid before the incubation. Hippuric acid that was formed during incuba-
tion was extracted with 1.5 ml of ethylacetate by mixing. After centrifugation I ml of 
the organic layer was transferred to a new tube. The ethylacetate was evaporated and 
2 ml of a NaCl solution (I moll!) was added, followed, after mixing, by 2 ml of light 
petroleum (boiling point 40-60°C). The samples were then mixed and after centrifu-
gation the light petroleum layer was removed by aspiration. The absorbance at 228 
nm was read in a 1-cm quartz cuvette. The absorbance of the blank was substracted 
from the absorbance ·of the corresponding test sample. Results are expressed in milli-
units per millilitres of plasma, one unit being the quantity of enzyme that produces 
one micromole of hippuric acid per minute. The production of hippuric acid from 
hippuryl-L-histidyl-L-leucine was linear with time for at least one hour upto levels of 
80 m-units/ml. Samples were assayed in duplicate. Both intra- and inter-assay coef-
ficients of variation were less than 5%. 
Active. renin. The concentration of enzymatically active renin in plasma was measured 
as described by Derkx et al (29,30). Blood was collected in chilled plastic tubes 
containing disodium ethylenediaminetetra-acetate (EDTA) in a final concentration of 
5 mmolll. Blood was centrifuged at 4°C immediately after collection. Plasma was 
kept frozen at -20°C before use. Aliquots (0.10-0.25 ml) were added to 0.5 ml of renin 
substrate, and the volume was adjusted to 1.0 ml with phosphate buffer pH 7.5. Renin 
substrate was prepared from plasma of nephrectomized sheep. The final concentration 
of renin substrate in the incubation mixture was 2.5 ,umol/l Ile5-angiotensin I equiva-
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Ients, which corresponds with aboutiO times KM. After addition of 10 J.<l of 0.34 
moll! 8-hydroxyquinoline, 5 J.<l of 0.28 mol/! phenylmethylsulphonyl-fluoride in 
ethanol and 10 J.<l of aprotinin (10,000 kallikrein-inhibiting units/ml) the mixtures 
were incubated for three hours at 37°C. Parallel incubations at 4°C served as blanks. 
After incubation l ml ofNaCl (0.15 moll!) was added and the mixture was heated for 
ten minutes in a boiling water bath and centrifuged. The concentration of angiotensin 
I in the supernatant was measured by radioimmunoassay, using 125 I~labeled Ile5-
angiotensin I and rabbit anti-Ile5-angiotensin I anti-serum. Semipurified human renal 
renin (MRC-standard 68/356) was used as an external standard (31). Renin concen-
tration is expressed as J.<-units of this standard per ml of plasma (J.<U/ml). The inter-
assay variability was evaluated by weekly measurements of active renin in standard 
normal plasma. The mean value of active renin was 27±3 i'U/ml for 36 assays 
(coefficient of variation II%). Normal values in I 7 healthy male subjects, who were 
recumbent for at least one hour before sampling and had a daily sodium intake of 50 
mmol ranged from 14-43 J.<U/ml. 
Noradrenaline. For the determination of plasma noradrenaline the radioenzymatic 
method described by Henry et al (32) was used. The method is based on the principle 
that noradrenaline in the presence of a radiolabeled methyldonor (S-adenosyl-L-
(methyl-'H) methionin, 3H-SAM) is converted by the enzyme phenylethanoiamine-N-
methyl transferase (PNMT) into radiolabeled adrenaline. Ten ml of blood was 
collected into chilled tubes containing heparin and !5 mg gluthatione to prevent 
noradrenaline breakdown. Immediately after collection the tubes were put on ice and 
centrifuged at 4°C for 10 minutes. Immediately thereafter plasma (4.5 ml) was 
removed and deproteinized by adding 0.5 ml of 3 mol/1 trichloroacetic acid under 
vigorous stirring. After centrifugation at 4°C for 15 minutes the supernatant was 
removed and stored at -20°C until assayed. The assay was performed by incubating 
l 00 I' l portions of the deproteinized plllsma at 37°C with 5 i'Ci of3H-SAM (Radio-
chemical centre, Amersham. UK; !0-15 Ci/mmol) and with PNMT, which was pre-
pared according to the directions of Molinoff et al (33). After one hour the incubation 
was stopped by adding Tris-phosphate buffer of pH 8.6 and the adrenaline formed was 
absorbed on acid-washed alumina as described by Anton and Sayre (34). Repeated 
washings with distilled water and precipitation with phosphotungstic acid removed 
most of the excess 3H-SAM. The radioactive adrenaline was taken up in toluene 
containing 2% of diethylhexylphosphoric acid and counted for I 0 minutes in a scintil-
lation counter after addition of scintillation liquid (8 g of butyl-PBD (2-( 4-t-
butylphenyl)-5-(4-biphenylyl)-1,3,4-oxadiazole). All measurements were made in 
duplicate, both with and without an internal standard (500 pg of noradrenaline). 
Blanks were prepared by substituting 0.3 moll! trichloroacetic acid for deproteinized 
plasma. In each assay batch samples of a plasma pool were included. Inter- and 
intra-assay variability coefficients were less than 10%. Normal values are 100-450 
pg/ml in the recumbent patient. 
Other determinations. Blood haematocrit was measured by the microcentrifuge 
method using oxalate as the anticoagulant (35). Sodium and potassium in plasma and 
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urine were measured by a flame photometric method. Plasma was prepared by using 
lithium heparin as the anticoagulant. Creatinine was measured in serum and urine 
according to Jaffes alkaline picrate reaction. The measurements were made by the 
central laboratory for clinical chemistry at the university hospital. 
2.8. Calculation of radiation dose 
The mean absorbed doses resulting from the isotopes used in the in vivo investigations 
described in this thesis were calculated from the tabulated 'S-values' (absorbed dose 
per unit cumulated activity) of the various isotopes (36). 
Isotope Activity Dose Mean absorbed dose 
(MBq) (mGy/MBq) (mSv) 
"S (sulphate) 0.25 0.10 0.025 
99mTc-(albumin) 7.40 0.08 0.592 
125!-( thalamate) 0.56 0.04 0.022 
131!-(hippuran) 2.22 0.23 0.511 
Comparing these figures with those of the normal environmental radiation (2 mSv per 
year), the allowed yearly dose for general members of the public (5 mSv) and for 
radiological workers (50 mSv) and with X-ray investigations (0.5-8 mSv), we feel 
well justified to use these methods. 
2.9. Statistics 
Results are expressed as mean±standard error of the mean (mean±SEM). All values 
relevant to body size were converted to 1.73 m2 body surface area. For comparison of 
results Student's t-test for paired and unpaired data was used. Correlations between 
parameters were assessed by linear regression analysis. Differences between results 
and correlation coefficients were considered to be significant at a p-value less than 
0.05. 
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CHAPTER 3 
Haemodynamic profile of captopril treatment m 
various forms of hypertension 
3.1. Summary 
The effects of captopril 450 mg/ day for four weeks on blood pressure, heart rate, 
cardiac output and extracellular fluid volume were compared in severe, often drug-
resistant hypertension (n=23), mild to moderate hypertension associated with renal 
artery stenosis (n = 10) and mild to moderate essential hypertension (n=20). Plasma 
renin in the three groups was 52±19. 58±17 and 20±4 I'U/ml (mean±SEM), 
respectively. Blood pressure fell by 18±4%, 21±2% and 18±1%. The pressure drop 
was mainly due to a fall in peripheral vascular resistance. Addition of the diuretic 
hydrochlorothiazide (25-100 mg/day) caused a further fall in resistance. Despite the 
vasodilator effect of captopril, reflex cardiostimulation and reactive fluid retention 
were not observed. In severe hypertension, captopril alone was more effective in 
lowering blood pressure than combined diuretic-betablocker-vasodilator therapy. 
Moreover, cardiac output in these patients was higher and resistance was lower after 
captopril than during combined treatment. Thus, captopril was capable of normalising 
the abnormal haemodynamic state in patients with essential hypertension and in 
hypertension associated with renal artery stenosis. Despite marked differences in 
pre-treat:rp.ent plasma renin. the effects of captopril on systemic haemodynamics were 
similar in all the patients. 
3.2. Introduction 
The orally active angiotensin !-converting enzyme inhibitor, captopril, belongs to a 
new class of antihypertensive agents, which may offer certain advantages over estab-
lished drugs (1.2). 
The efficacy of captopril in reducing blood pressure has been amply demonstrated in 
various forms of hypertension (3-8), but its effect, particularly during chronic treat-
ment, has not been defined in terms of cardiac output and vascular resistance. Apart 
from a study by Atkinson eta! (9), indicating that total exchangeable sodium had not 
changed after six weeks of captopril in eight patients with renal artery stenosis, there 
are few data on fluid balance during long-term captopril therapy. Information on 
these points is important, because it may help to delineate more clearly the place of 
this drug among the antihypertensive drugs now in common use. 
We report here on a comparative study undertaken to collect such data in 1) severe, 
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often drug-resistant hypertension, 2) mild to moderate hypertension associated with 
renal artery stenosis, and 3) mild to moderate essential hypertension. In the group 
with severe hypertension, combined diuretic-betablocker-vasodilator treatment was 
compared with captopril alone and with captopril plus diuretic. 
33. Methods 
All measurements were made while the patients were recumbent for at least one hour. 
Blood pressure was measured with the London School of Hygiene sphygmomanome-
ter (I 0) to minimise observer bias. Phase V was taken as diastolic pressure. Three 
consecutive readings were averaged. Cardiac output waS determined by a non-
invasive radioisotope dilution technique (II). Heart rate was calculated from a simul-
taneously recorded ECG. Immediately after the precordial time-radioactivity curve 
had been recorded, blood pressure was measured in triplicate, the average value of 
mean arterial pressure [diastolic pressure+ 0.3 X (systolic pressure- diastolic pres-
sure)] being used for calculating total peripheral resistance. Blood samples were then 
taken for measuring extracellular fluid volume (!2) and active renin in plasma (13). 
The results presented here were obtained while the subjects were followed as out-
patients. The patients were advised to take a diet containing sodium 100 mmol/day. 
Adherence to this advice was not rigorously checked, but spot 24-h urine collections 
before and after four weeks of captopril in 30 patients gave values of 112±8 and 
108±10 mmol sodium, respectively. 
Measurements were made three to four hours after the morning dose of captopril or 
placebo. For blood pressure measurements the patients were seen weekly in the 
placebo-period and during the first eight weeks of captopril. Thereafter, they were 
seen at intervals of four weeks. Cardiac output, extracellular fluid volume and plasma 
renin were determined before captopril and after four weeks of captopril450 mg/day. 
3.4. Patients and study protocol 
Fifty-three consecutive patients (Table l ), who had been referred to the hypertension 
clinic, were studied after they had given their informed consent to the procedures. 
Severe hypertension. Twenty-three patients had a blood pressure of 200/130 mm Hg 
or higher at two or more visits to the outpatient clinic. Twelve patients had been 
untreated for at least two weeks while these pressures were recorded. Plasma renin 
was elevated in four of them. Eleven patients were on multiple drug therapy and 
remained hypertensive (!60/100 mm Hg or higher) despite a 2-week course of so-
called standard triple therapy, i.e. a combination of a diuretic (hydrochlorothiazide 
100 mg/day or furosemide 80 mg/day) with a beta-adrenoceptor blocking agent 
(propranolol 320 mg/day) and a vasodilator (hydralazine 200 mg/day). A previous 
period of accelerated or malignant hypertension with bilateral retinal haemorrhages 
and exudates has been documented in 12 cases. In five patients hypertension was 
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TABLE 1: BLOOD PRESSURE AND RENIN IN THE THREE PATIENT-GROUPS 
Patient-group No Sex Age Blood pressure Renin 
(male) (yc) (mm Hg) (~U/ml) 
Systolic Diastolic 
Severe hypertension 23 19 51± 3 227 ± 11 142 ± 4 52± 19 
Mild to moderate hypertension 
associated with renal artery stenosis 10 3 37 ± 4 181 ± 8 106 ± 4 58± 17 
Mild to moderate 
essential hypertension 20 17. 47 ± 2 170 ± 4 106 .:t 2 20 ± 4 
Blood pressure and renin values in severe hypertension are those before standard triple therapy (see text) 
and captopril were begun. The values in mild to moderate hypertension are those measured in the last week 
of placebo. Normal range of plasma renin is 15-40 p;U/mL 
associated with renal artery stenosis, and in 12 with impaired renal function (serum 
creatinine !50-400 ,umol/1). Patients were taken into hospital and, after previous 
medication had been stopped, captopril was begun in a dose of 25 mg orally, which 
was gradually increased to 450 mg/day, divided into three doses. The patients were 
then followed in the out-patient clinic. Blood pressure became normal on captopril 
alone in six patients. The remainder became normotensive after hydrochlorothiazide 
(25-100 mg/day) had been added. 
Mild to moderate hypertension associated with renal artery stenosis. This group consis-
ted of ten patients. Blood pressure after treatment had been stopped for at least three 
weeks was !50-200 mm Hg systolic and 90-120 mm Hg diastolic. They were admitted 
to hospital for renal arteriography and renal vein renin sampling, because of a unilate-
ral abnormality on intravenous urography and/or radioisotope renography, which 
was suggestive of renal artery stenosis. Peripheral venous renin was elevated in seven 
patients. Renal arteriography was performed after the renal vein and artery samples 
had been collected, and it showed unilateral renal artery stenosis. The renal vein-to 
artery ratio of renin on the side of stenosis was 1.5-3.4. Patients were followed as 
out-patients for four weeks while on placebo. Captopril was then begun in a dose of 
25 mg, which was increased over four weeks to 450 mg/day, divided into three doses. 
At the time of the study all patients had been on captopril for at least two months. By 
the time of preparation of this report six patients had undergone surgery, and in them 
three months later blood pressure was 160/90 mm Hg or less without medical 
treatment. 
Mild to moderate essential hypertension. This group consisted of 20 patients. Routine 
investigations, including intravenous urography and radioisotope renography, had not 
revealed any cause for the hypertension. Blood pressure while the patients were 
untreated was 140-200 mm Hg systolic and 95-120 mm Hg diastolic. Plasma renin 
was elevated in two patients, it was normal in 12 and low in six. As in the previous 
group, captopril was begun after a 4-week placebo period, and the dose was increased 
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from 25 to 450 mg/day. At the time of this analysis. all patients had been on captopril 
alone for at least two months, and 12 patients for more than one year. 
Data are presented as mean±SEM. Student"s t-tests for paired and unpaired data were 
used for statistical analysis. 
3.5. Results 
After four weeks of captopril alone (450 mg/day), mean arterial pressure had fallen 
by 29±6 mm Hg (18±4%) in severe hypertension, by 29±3 mm Hg (21 ±2%) in 
mild to moderate hypertension associated with renal artery stenosis, and by 23±3 mm 
Hg (18± I%) in mild to moderate essential hypertension (Fig. 1,2). The pressure 
changes were not significantly different, despite the differences in plasma renin. Blood 
pressure became 150/90 mm Hg or less in six out of 23 patients with severe hyperten-
sion, in eight out of ten patients with· mild to moderate hypertension associated with 
renal artery stenosis and in 16 out of 20 patients with mild to moderate essential 
hypertension. The hypotensive effect did not wear off with continued use of captopril 
over periods of more than one year. 
In the patients with severe hypertension, the fall of blood pressure after four weeks of 
captopril monotherapy was paralleled by a fall in resistance. Blood pressure on cap-
topril was significantly lower than during combined treatment with a diuretic, beta-
adrenoceptor blocking agent and a vasodilator (Fig. I). Moreover, cardiac output was 
higher and total peripheral resistance was lower on captopril than during triple the-
rapy. Both pressure and resistance fell further when a diuretic was added to captopril 
(Fig I). 
In the patients with mild to moderate hypertension and renal artery stenosis cardiac 
output was unchanged after captopril, and in mild to moderate essential hypertension 
cardiac output was slightly lowered. In both groups with mild to moderate hyperten-
sion the fall in blood pressure was associated with a fall in resistance and, as in severe 
hypertension, the change in resistance was the main cause of the fall in pressure (Fig 
2). 
In contrast to many vasodilators, captopril did not cause reflex~cardiostimulation, and 
heart rate and stroke volume did not rise. Also unlike many vasodilators, captopril did 
not lead to fluid-retention, as judged from measurements of extracellular fluid 
volume. In the group with mild to moderate essential hypertension, a significant 
decrease in extracellular fluid volume was observed. 
Plasma renin rose from 52± 19 to 31 0±83 I'U/ml after four weeks of captopril ( 450 
mg/day) in severe hypertension; it rose from 58±17 to 410±72 I'U/ml in mild to 
moderate hypertension associated with renal artery stenosis, and from 20±4 to 
98±22 I'U/ml in mild to moderate essential hypertension. Serum creatinine was 
unchanged after captopril alone. Some decline in renal function occurred in the 
patients who received both captopril and diuretic; creatinine rose by ll ±2%. 
Adverse reactions. Six patients developed a maculopapular skin rash. Two patients 
complained of loss of taste. These adverse reactions disappeared while.the drug was 
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Figure 1. Effects of captopril 450 mg/day for four weeks in severe hypertension. Comparison with standard 
triple therapy (sec text) and with captopril plus hydrochlorothiazide 25-100 mg/day for four weeks. 
Systolic. diastolic and mean arterial pressures are indicated. Numbers of patients: left panel. 12; middle 
panel. 11; right panel. 10. >~<=p<0.05. **=p<O.OL ***=p<O.OOI. 
continued. One patient with severe drug-resistant hypertension and renal parenchy-
mal disease (endogenous creatinine clearence 15-20 mllmin), who was on captopril 
450 mg/ day and hydrochlorothiazide 100 mg/day for one year, developed oedema of 
the face. Both captopril and hydrochlorothiazide were withdrawn. The signs cleared 
within 24 hours and had disappeared after a week. Because blood pressure control 
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Figure 2. Effects of captopril450 mg/ day for four weeks in mild to moderate hypertension associated with 
renal artery stenosis (left panel), and in mild to moderate essential hypertension (right panel). Measure~ 
rnents during captopril therapy are compared with those in the fourth week of placebo treatment. Systolic, 
diastolic and mean arterial pressures are indicated. Numbers of patients: left panel. 10; right panel. 20. 
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was lost, captopril was given again, but in a dose of 100 mg/day and hydrochlorothia-
zide was added two weeks later. With this treatment satisfactory blood pressure 
control was achieved without any adverse effect. 
3.6. Discussion 
It has recently been advised to restrict the use of captopril, at least for the time being, 
to patients with severe hypertension and to cases with renovascular hypertension. This 
advice is sensible because captopril is very effective in these patients, even when 
established drugs have failed ( 14, 15). The advice also seems logical because an attack 
on the renin-angiotensin system is thought to be a major component of the hypoten-
sive effect of captopril; plasma renin is often elevated in accelerated or malignant 
hypertension and in hypertension associated with renal artery stenosis. This study 
confirms the efficacy of captopril in severe, often high-renin, hypertension. In addition 
the data show that the drug is no less effective in mild or moderate hypertension, no 
matter whether plasma renin is high or low. Other factors than inhibition of plasma-
renin-mediated angiotensin II formation may be important for the hypotensive effect 
of converting-enzyme inhibition (16-20). 
A 20% reduction in both systolic and diastolic pressures was observed with mild 
dietary sodium restriction and captopril as the only drug. This response is as good as 
or even better than tho,e obtained with thiazide diuretics (21) or beta-adrenoceptor 
blocking agents (22,23). Captopril has an almost ideal haemodynamic profile. It 
lowers vascular resistance with little or no effect on cardiac output. The drug produces 
vasodilatation, but does not cause the usual side effects of vasodilatation, such as 
reflex tachycardia and fluid retention by the kidneys. 
It is not clear why vasodilatation after captopril does not lead to baroreflex-mediated 
cardiostimulation. The absence of fluid-retention after captopril can be explained, at 
least in part, by reduced angiotensin ll formation, since this peptide is known to 
promote renal tubular sodium reabsorption both directly and via aldosterone. A 
similar mechanism might underly the favourable haemodynamic response to the com-
bination of captopril with a diuretic (14). Our patients showed a sustained reduction 
of extracellular fluid volume after hydrochlorothiazide had been added to captopril. 
This was associated with a significant fall in vascular resistance. Presumably, inhibi-
tion of angiotensin I conversion in these patients bas prevented the compensatory rise 
in angiotensin II and aldosterone, which can limit the therapeutic effect of diuretics 
(24,25). 
While there are no signs of increased adrenergic nervous activity counteracting the 
hypotensive effect of captopril, there is also no indication that the baroreflex-
mediated response to upright posture is impaired by captopril, so that postural hypo-
tension is seldom seen (26). From experiments in dogs there is even some evidence 
that the set point, but not the sensitivity, of the baroreflex is altered by converting-
enzyme inhibition (27). 
Some severe adverse reactions to captopril have been reported, including pemphigus-
like skin eruptions, nephrotic syndrome, leucopenia and agranulocytosis. Such reac-
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tions, however, have mostly been observed when hypertension was associated with 
renal disease, systemic lupus erythematosus or scleroderma, or when the patients were 
on immunosuppressive therapy. The incidence of such severe reactions in patients 
with uncomplicated hypertension seems less than I% (28). Minor side effects, such as 
skin rash and taste disturbance, have been observed in about 14% of the hypertensive 
patients in a large series (28), which agrees with the incidence of 17% in the present 
study. Cutaneous reactions may be dose-related (29), and it is important that lower 
doses than originally recommended may be used without loss of therapeutic effect 
(19). 
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CHAPTER4 
Haemodynamic effects of captopril in essential 
hypertension, renovascular hypertension and 
cardiac failure: correlations with circulating renin 
4.1. Summary 
The haemodynamic effects of captopril were investigated in 22 patients with essential 
hypertension, 22 with hypertension and renal artery stenosis and 14 with refractory 
chronic heart failure. The effects of a first dose .of captopril, 50 mg orally, were 
observed for two hours, and the effects of repeated doses. 450 mg/ day in combination 
with mild dietary sodium restriction, for at least four weeks. 
Shortwterm captopril treatment caused similar reductions in blood pressure in the 
three patient groups, that is, 21 ±3 mm Hg in essential hypertension, 29±6 mm Hg in 
renovascular hypertension and 21±2 mm Hg in heart failure (mean±standard 
error of the mean) despite large differences in pretreatment plasma renin. Heart rate 
and cardiac output did not change in hypertensive patients, and cardiac filling pressu-
res decreased. The changes in right atrial pressure, pulmonary artery pressure and 
pulmonary capillary wedge pressure in essential hypertension and in renovascular 
hypertension did not differ. Heart rate decreased and cardiac output increased in heart 
failure, whereas cardiac filling pressures decreased. Blood pressure responses to long-
term captopril therapy in essential and in renovascular hypertension were similar and, 
as with shortwterm treatment, changes in blood pressure were largely determined by 
changes in peripheral resistance. Serial measurements of extracellular fluid volume 
showed no evidence of fluid retention by the kidneys. 
Short·term but not longwterm blood pressure responses were correlated with pretreat-
ment plasma renin (percent change in mean arterial pressure, short-term, versus log 
renin, r=0.47, p<O.Ol, n=44). Both short- and long-term responses of total periphe-
ral resistance were correlated with plasma renin (percent change in resistance, short-
term versus log renin, r=0.64, p<O.OOl, n=40; percent change in resistance, long-
term versus log renin, r=0.56, p<O.OOI, n=31). The correlations were weak and 
probably not important for clinical practice. These data indicate that other factors 
besides circulating renin are important in captopril's hypotensive effect. The favoura-
ble haemodynamic effects of converting enzyme inhibition warrant further considera-
tion of this principle of therapy in the clinical management of most forms of hyperten-
sion and also in the treatment of chronic heart failure. 
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4.2. Introduction 
The efficacy of captopril in decreasing blood pressure has amply been demonstrated. 
Several but not all centers reported the drug to be more effective in hypertension when 
plasma renin is high rather than low (1,2). Positive correlations were observed 
between the decrease in blood pressure shortly after a single dose of captopril and 
pretreatment plasma renin (3,4). Such correlations were also recorded after long-term 
treatment (4,5) but again not invariably so (6-10). Theoretically, the change in vascu-
lar resistance after captopril might correlate more closely with pretreatment renin 
than does the change in blood pressure. Other differences between haemodynamic 
responses in patients with high-renin and low-renin hypertension may exist. Compara-
tive studies to explore this possibility are scarce. Apart from a study by Atkinson et al 
( ll) indicating that total exchangeable sodium had not changed after six weeks of 
captopril therapy in eight patients with renal artery stenosis, there are few data on 
fluid balance during long-term captopril treatment. Such information is important 
because it may help to delineate more clearly the place of this drug among the 
antihypertensive drugs now in common use. 
We have collected such data in patients with essential hypertension and in those with 
hypertension associated with renal artery stenosis. The results were compared with 
observations in so-called refractory chronic heart failure. Plasma renin was low or 
normal in essential hypertension, normal or high in renal artery stenosis and grossly 
elevated in most cases with heart failure. 
4.3. Patients and methods 
Forty-four hypertensive and 14 normotensive patients with chronic heart failure were 
studied after they had given their informed consent to the study protocol and 
procedures. 
Essential hypertension. Twenty-two patients (seven women), aged 48±2 years, were 
studied. Routine investigations including intravenous urography and radioisotope 
renography had not revealed any cause for the hypertension. In 17 patients previous 
antihypertensive therapy, if any, was tapered off and a placebo was given for at least 
three weeks. Blood pressure on placebo was 140 to 200 mm Hg systolic and 95 to 120 
mm Hg diastolic. Five patients remained on multiple drug therapy. In these five 
patients blood pressure was 160/ l 00 mm Hg or higher despite a two week course of 
standa_rd triple therapy, that is, a combination of a diuretic (hydrochlorothiazide (l 00 
mg/ day or furosemide 80 mg/ day) with a beta-adrenoceptor blocking agent (propra-
nolol 320 mg/day) and a vasodilator (hydralazine 200 mg/day) 
Hypertension associated with renal artery stenosis (renovascular hypertension). This 
group consisted of 22 patients (nine women), aged 42±4 years. Renal arteriography 
and renal vein sampling. was performed because of abnormalities found on routine 
intravenous urography or radioisotope renography, or both. In 18 patients unilateral 
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and in four patients bilateral renal artery stenosis was demonstrated. The renal vein-
to-artery ratio of renin on the side of stenosis ranged from 1.5 to 4.6. Of these 22 
patients. 16 were treated by placebo for at least two weeks. Blood pressure on placebo 
was 150 to 200 mm Hg systolic and 95 to 120 mm Hg diastolic. Six remained on 
standard triple therapy for at least two weeks. 
Chronic heart failure. Fourteen patients (three women), aged 52±2 years, were 
studied. Nine had ischemic heart disease and five had valvular disease. In four of the 
latter patients one or more prosthetic valves had been placed. All had refractory 
congestive heart failure and were in functional class IV (New York Heart Association) 
while under treatment with digoxin, a diuretic (furosemide 80 to 120 mg/day) and 
vasodilators (either hydralazine and isosorbide dinitrate or prazosine). 
Patients with hypertension. The study in these patients was divided into four phases: 
an initial outpatient precaptopril evaluation during placebo or standard triple therapy 
(phase 1). an inpatient captopril titration period (phase II). an outpatient follow-up 
period of at least four weeks during captopril monotherapy ( 450 mg/ day) (phase Ill). 
and in some patients a final period in which a diuretic was added to captopril (phase 
!V). 
AU measurements in phase I were made when the patients had been recumbent for at 
least one hour. Noninvasive measurements of cardiac output (vide infra) were begun 
when the patients were on placebo or standard triple therapy for at least two weeks. 
Dietary advice to restrict sodium intake was given but adherence to this advice was 
not rigorously checked. However, spot 24-hour urine collections in 30 patients during 
phases I and Ill gave values of 1!2±8 and 108±10 mmol of sodium. respectively. 
For initiation of captopril treatment in phase II, patients were admitted to the hospital 
for a few days. The haemodynamic effects of a single first dose of captopril. 50 mg 
orally, "Yere observed for several houfs by invasive techniques in 14 patients with 
essential hypertension and in 16 with hypertension and renal artery stenosis. None of 
them had been on active drug for at least three weeks. Eleven patients on standard 
triple therapy were slowly titrated with increasing doses of captopril on an eight hour 
schedule. while triple therapy was tapered off. In all patients a final daily dose of 450 
mg was reached in a few days. 
After discharge all patients were followed up in phase Ill in the outpatient clinic. 
Noninvasive measurements of cardiac output, which had been performed in phase I, 
were now repeated at weekly intervals. Therapy compliance was checked by pill 
counting. 
In phase IV the haemodynamic effects of adding hydrochlorothiazide. 25 to 100 
mg/day. to captopril. 450 mg/day. were studied in patients who did not become 
normotensive ( 150/90 mm Hg or less) on captopril alone. 
Patients with chronic heart failure. Au patients were admitted to the coronary care 
unit and the withdrawal of previous vasodilator therapy was covered by invasive 
monitoring. Twenty-four hours after the last dose of vasodilator and 12 hours after the 
last dose of diuretic, captopril 50 mg was given and the effects were observed for 
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several hours. 
Haemodynamics. All haemodynamic studies were performed while the patients were 
in the postabsorptive state and when they had been recumbent for at least one hour. 
The short-term effects of captopril were monitored invasively and the measurements 
were begun one hour after the catheters had been placed. Systemic arterial pressure 
was measured through a catheter introduced into a radial or brachial artery. A Swan-
Ganz flow-directed triple lumen catheter was introduced by way of an antecubital 
vein for recording right atrial, pulmonary artery and pulmonary capillary wedge 
pressures. Cardiac output was measured in triplicate by thermodilution technique. 
Blood pressure. Noninvasive methods were used for repeated measurements before 
and during long-term captopril treatment. Blood pressure was measured with the 
London School of Hygiene sphygmomanometer to minimize observer bias (12). 
Disappearance of sounds was taken as diastolic pressure. 
Cardiac output. This was measured by an indicator dilution technique using 99 mtech-
netium human serum albumin (100 to 200 ,u.Ci). Time-concentration curves were 
recorded by precordial counting of radioactivity. The counting probe, which was 
described previously ( 13), was placed perpendicular to the chest wall without lateral 
rotation. over the fifth rib at the midsternal line with the patient supine. Response 
curves were recorded for one to two minutes after rapid intravenous injection of the 
isotope. Additional recordings were made after five and 10 minutes when blood 
samples were taken. Cardiac output was calculated with the Stewart-Hamilton for-
mula. From duplicate measurements in 30 subjects with cardiac output values ranging 
from four to 12liters/min the coefficient of variation was calculated to be six percent. 
Simultaneous measurements of cardiac output by the classical indocyanine dilution 
method and by the isotope method showed good agreement (r=0.92, n=37). Heart 
rate was calculated from a continuously recorded electrocardiogram. Immediately 
after the precordial time-radioactivity curve was recorded, blood p.ressure was measu-
red in triplicate. Mean blood pressure (diastolic pressure+ 0.3 X pulse pressure) was 
used for calculating total peripheral resistance. 
Extracellular fluid volume was estimated by measuring the distribution volume of 
intravenously injected sodium 35S sulphate (8 to 12 I'Ci) with blood sampling at 0, 30, 
60, 80, 100 and 120 minutes (14). Blood samples were also drawn for determination 
of active plasma renin. The normal range of plasma renin is 15 to 40 !' U /ml (15). All 
values relevant to body size were converted to 1.73 m' body surface area. 
Data are presented as mean values±standard error of the mean. The t-tests for paired 
and unpaired data were used for comparison. 
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4.4. Results 
Short-term studies 
Blood pressure and haemodynamic effects (Fig 1). The effects of 50 mg of captopril 
were maximal at 90 minutes. At that time mean arterial pressure had decreased from 
141±6 to 119±7 mm Hg in patients with essential hypertension (n=l4), from 
143±6 to 114±5 mm Hg in those with hypertension with renal artery stenosis 
('renovascular') (n = 16) and from 76±3 to 54±4 mm Hg in those with chronic heart 
failure (n = 14 ). These responses were not significantly different among the three 
patient groups (p>0.05). Heart rate and cardiac output did not change in the two 
hypertension groups. Heart rate decreased from 90±4 to 82±3 beats/min (p<O.Ol) 
in the chronic heart failure group and cardiac output increased from 4.3±0.5 to 
5.2±0.1 liters/min (p<0.05). Right atrial pressure. pulmonary artery pressure and 
pulmonary capillary wedge pressures decreased in the three patient groups. The chan-
ges in these pressures were greater (p<O.Ol) in chronic heart failure than in essential 
hypertension and renovascular hypertension. 
Total peripheral resistance decreased from 2170±90 to 1880±90 dyn s cm-5 in 
essential hypertension; from 1980± 160 to 1600± 130 dyn s em_, in 'renovascular' 
hypertension and from 1360±210 to 770±130 dyn s cm-5 in chronic heart failure. 
The resistance changes were greater (p<0.05) in heart failure than in the two hyper-
tensive groups. 
Plasma renin. Plasma renin increased from 27±6 I'U/ml before captopril to 79±30 
I'U/ml 90 minutes after captopril in essential hypertension. It increased from 
!10±21 to 700±120 I'U/ml in renovascular hypertension and from 740±330 to 
2700±870 I'U/ml in chronic heart failure. 
Long-term studies 
Captopril mon01herapy in essential and· renovascular hypertension (Fig. 2). Mean 
blood pressure had decreased froni 136±4 to 108±2 mm Hg after four weeks of 
captopril therapy, 450 mg/day, in the essential hypertension group (n = 17) and from 
135±4 to 105±3 mm Hg in the renovascular hypertension group (n=l4). These 
responses in the two patient groups were not significantly different. Heart rate in the 
essential hypertension group was 76±3 beats/min before captopril and 69±2 after 
four weeks of captopril therapy. Cardiac output was 5.5±0.2 liters/min before the 
drug and 4.8±0.2 after four weeks. These changes were statistically significant 
(p<O.OS). Stroke volume was not significantly altered in the essential hypertension 
group. There were no significant changes in heart rate, cardiac output and stroke 
volume in the renovascular hypertension group. Total peripheral resistance decreased 
from 2070 ± 130 to 1830 ±92 dyn s em_, in the essential hypertension group and from 
1940±87 to 1470±69 in the renovascular hypertension group, the change in resis-
tance being greater (p<O.Ol) in the latter group. 
Extracellular fluid volume in the essential hypertension group was 14.8 liters before 
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captopril and 14.0 liters after four weeks. In the 'renovascular' hypertension group it 
was 14.2 and 14.1 liters, respectively. The difference was statistically significant 
(p<0.05) only in the essential hypertension group. 
Plasma renin activity increased from 19±4 ,uU/ml before captopril to 100±30 
I'U/ml after four weeks of captopril therapy, 450mg/day, in the essential hyperten-
sion group and from 75±19 to 570±130 fLU/ml in the 'renovascular' group. 
Captopril monotherapy versus standard triple therapy (Fig. 3). The haemodynamic 
effects of four weeks of captopril monotherapy, 450 mg/day, and four weeks of 
standard triple therapy were compared in a group of ll patients including five with 
e$.sential hypertension and six with hypertension and renal artery stenosis. Systolic 
and diastolic arterial pressures were lower (p<0.05) with captopril than with stan-
dard triple therapy (Fig. 3). Moreover, cardiac output was higher (p<0.05) and total 
peripheral resistance was lower (p<O.Ol) with captopril. 
Captopril monotherapy versus captopril plus a diuretic (Fig. 3). The haemodynamic 
profiles of four weeks of captopril alone, 450 mg/ day, and four weeks of captopril 
plus hydrochlorothiazide, 25 to l 00 mg/ day, were compared in ten patients with 
essential hypertension who did not become normotensive (150/90 mm Hg or less) 
on captopril alone. The addition of hydrochlorothiazide to captopril treatment caused 
a sustained decrease in extracellular fluid volume with further reduction in blood 
pressure. Heart rate and cardiac output showed no significant changes. Thus, the 
decrease in blood pressure was associated with a parallel decrease in total peripheral 
resistance. 
Correlations between haemodynamic responses and pretreatment plasma renin (Fig. 
4). Short-term blood pressure responses 90 minutes after 50 mg of captopril in the 
three groups of patients combined were correlated with pretreatment plasma renin 
(percent change in mean arterial pressure versus log renin, p<0.01, n=44). The 
correlation was rather weak (r=0.47) and was not significant in the essential hyper-
tension and heart failure groups separately. Short-term responses of total peripheral 
resistance were more closely correlated with pretreatment plasma renin (percent 
change in total peripheral resistance versus log renin, r=0.64, p<O.OOI, n=40). 
Long-term responses of mean blood pressure were unrelated to pretreatment plasma 
renin, whereas long-term responses of total peripheral resistance did correlate with 
pretreatment renin (r=0.56, p<O.OOl, n=3l). 
4.5. Discussion 
Blood pressure effects versus plasma renin. The hypotensive effects of captopril in 
essential hypertension and in hypertension with renal artery stenosis ('renovascular") 
appeared to be similar in this study despite fourfold higher plasma renin activity in the 
'renovascular' hypertension group. A weak, albeit statistically significant correlation 
was observed between the short-term hypotensive effect of captopril and pretreatment 
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renin in the group with renal artery stenosis and in this group and the essential 
hypertension group together but not in the essential hypertension group alone. No 
such correlations between blood pressure response and renin were observed during 
long-term captopril therapy (Fig. 4). 
The decrease in blood pressure was mainly caused by a decrease in peripheral resis-
tance in both hypertension groups. The changes in resistance in the two groups 
together were significantly correlated with pretreatment plasma renin both after short-
term captopril and after long-term treatment, but again the correlations were weak 
and were not significant in the individual groups (Fig. 4 ). 
Heart rate and cardiac output. Some statistically significant differences in the respon-
ses of heart rate and cardiac output to long-term captopril therapy between the two 
groups of hypertensive patients emerged. Heart rate and cardiac output decreased in 
those with essential hypertension and not in those with 'renovascular' hypertension, 
but here again the differences were small. 
Blood pressure and haemodynamic effeCls in heart failure. Plasma renin can be low, 
normal or high in chronic heart failure (16). In our patients it ranged from 30 to 4600 
I'U/ml (normal less than 40). By increasing peripheral vascular resistance the grossly 
elevated plasma renin in most of our patients might have contributed to the mainte-
nance of a relatively normal blood pressure in the presence of low cardiac output. 
However, despite the wide range of renin values, the effect of captopril on peripheral 
resistance was only weakly correlated with pretreatment renin values (Fig. 4 ). 
Blood pressure was already low in some patients with heart failure and a further 
decrease in pressure might have been deleterious, but captopril was well tolerated by 
these patients. They had no chest pain and there were no electrocardiographic changes 
suggestive of increased cardiac ischaemia. Within 30 minutes after the intake of 
captopril the patients were less dyspneic. Indeed, haemodynamic measurements sho-
wed improvement: heart rate decreased and cardiac output increased in the presence 
of marked reduction in cardiac filling pressures. These results agree with those of 
previous reports on the short-term effects ofcaptopril in heart failure (17,18). 
Mechanisms of captopril's cardiovascular effects. The most important haemodynamic 
effect of captopril is arteriolar dilatation. The arterioles are the major resistance to 
blood flow and form by far the largest contribution to total peripheral resistance. 
Therefore, correlations between captopril's effect on total peripheral resistance and 
pretreatment plasma renin support the contention that blockade of plasma renin-
mediated angiotensin II formation is a component of captopril-induced arteriolar 
dilatation. However, the correlation coefficients in our analysis were rather small and 
indicate that other factors besides circulating renin are important. The observed 
reduction in cardiac filling pressures has been considered to reflect a dilatory effect of 
captopril on capacitance vessels. However, it is more likely that reduced cardiac 
filling pressures are an expression of improved cardiac performance. Our data do not 
provide definite evidence for either possibility. 
Although captopril produces vasodilatation, it does not cause reflex tachycardia. 
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From experiments in animals (19) some evidence indicates that the set-point, but not 
the sensitivity, of the arterial baroreflex is altered by converting enzyme inhibition. In 
man the baroreflex-mediated responses to upright posture seem unimpaired by cap-
topril (20); postural hypotension is seldom seen with this drug. 
Extracellular fluid volume: role of angiotensin and aldosterone. Captopril does not 
cause fluid retention by the kidneys and again this contrasts with some other vasodila-
tors. The decrease in extracellular fluid volume observed in some of our hypertensive 
patients and the absence of fluid retention in all can be explained, at least in part, by 
reduced angiotensin II formation, because this peptide is known to promote renal 
sodium and water retention both through its direct actions on the kidney and through 
aldosterone. A similar mechanism could underlie the favourable haemodynamic 
response to the combination of captopril with a diuretic. Our patients showed a 
sustained reduction of extracellular fluid volume after· hydrochlorothiazide had been 
added to captopril, and this was associated with a deCrease in total peripheral resis-
tance. Presumably inhibition of angiotensin I conversion in these patients has preven-
ted the compensatory increase in angiotensin II and aldosterone, which can limit the 
therapeutic effect of a diuretic (21, 22). 
A 20 percent reduction in both systolic and diastolic blood pressures was observed in 
our hypertensive patients with captopril as the only drug in combination with mild 
dietary sodium restriction. This response is as good or even better than the blood 
pressure responses to thiazide diuretics and beta-receptor blocking agents. 
Therapeutic implications. Captopril is an effective antihypertensive ~gent with a 
favourable haemodynamic profile. The haemodynamic responses in essential hyper-
tension with low or normal plasma renin and in hypertension associated with renal 
artery stenosis with normal or high renin are very similar. The long-term haemody-
namic effects of converting enzyme inhibition that have been observed in patients 
with hypertension warrant further consideration of captopril as a treatment of choice 
in most forms of clinical hypertension. In severe or refractory chronic heart failure 
cardiac function can improve with captopril, but further studies are required to define 
its place in the long-term treatment of heart failure. 
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CHAPTER 5 
Effects of an angiotensin-converting enzyme 
inhibitor ( captopril) on blood pressure in anephric 
subjects 
5.1. Summary 
Randomised, double-blind cross-over trials were performed in seven anephric patients 
to determine the effect of the orally .active angiotensip.-converting enzyme inhibitor 
captopril on blood pressure in fluid-depleted and fluid-replete patients. Patients were 
given captopril, 100 mg orally, or placebo one hour after haemodialysis, when they 
were fluid depleted. Their mean (±SEM) supine blood pressure fell from 
127± 12/71 ±6 mm Hg before captopril to 106±13/54±4 mm Hg 24 hours after the 
drug, while on placebo it rose from 123±11173±5 mm Hg to 134±10/82±8 mm 
Hg. All patients developed orthostatic hypotension after captopril. In the fluid-replete 
state, two days after haemodialysis, captopril had no effect on blood pressure. The 
plasma concentration of active renin was extremely low and did not rise after fluid 
withdrawal or captopril. Thus the hypotensive effect of captopril did not appear to 
depend on circulating renin concentrations. 
The concept of 'renin-dependent' hypertension, which is responsive to captopril, as 
opposed to 'volume-dependent' hypertension, which is not responsive to captopril, 
may therefore be invalid. 
5.2. Introduction 
Peptidyldipeptide hydrolase, which converts angiotensin I into the potent vasocon-
strictor angiotensin II (angiotensin-converting enzyme) and degrades the vasodilator 
bradykinin (kininase II) (1), is inhibited by the orally active drug captopril 
(SQ14225) (2). Captopril's effectiveness as an antihypertensive agent has now been 
firmly established in both animals (1, 3-5) and man (6-8). The fall in arterial pressure 
after inhibition of the converting enzyme seems to be directly correlated with the 
pretreatment concentrations of circulating renin (9-11). It is therefore commonly 
believed that captopril lowers blood pressure mainly through its action on the renin-
angiotensin system (6, 7). The greater fall in pressure after stimulation of the renal 
release of renin by sodium and water depletion seems to support this view (7, 9-12). 
Captopril therefore seems to be a simple and useful tool for searching out those 
patients whose hypertension depends on overactivity of the renin-angiotensin system 
and who would benefit particularly from drugs that suppress this system (6, 9, 10, 
13). 
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Nevertheless, some data suggest that captopril given repeatedly over a period will 
lower blood pressure equally well in patients with low and normal renin concentra-
tions (6-8). We describe here a study to determine the hypotensive effect of captopril 
in anephric subjects after they had been treated with ultrafiltration. 
5.3. Patients and methods 
Seven anephric subjects (four men) aged 30 to 58 years who had been anephric for 
one to nine years participated in the study. All gave their informed consent to the 
study. The effects of captopril and placebo on blood pressure were first compared in a 
randomised, double-blind cross-over study when the patients were relatively fluid 
depleted. The patients underwent dialysis three times a week on a Rhodial-75 single-
patient unit with a RP-6 disposable polyacrylonitryl membrane kidney. The recircula-
ting dialysate contained 140 mmol sodium per liter. The mean (±SEM) loss of body 
weight per dialysis session was 1.8±0.2 kg on captopril and 2.0±0.2 kg on placebo. 
the difference being statistically insignificant (see Table). Four patients were given 
captopril I 00 mg orally, one hour after haemodialysis. The remaining three patients 
were given placebo, which was similar to the captopril tablet in taste, form, and 
colour. Two days later the patients who had been on captopril received placebo and 
vice versa, again one hour after haemodialysis. Blood pressure y.ras measured at 
15-minute intervals for two hours after the dose of captopril or placebo and again at 
24 hours. It was recorded in duplicate by the same investigators using a London 
School of Hygiene sphygmomanometer (MK4. no 7125) to avoid observer bias and 
digit preference. Heart rate was computed from a continuous electocardiographic 
(ECG) tracing. 
One week later the patients underwent a second trial with captopril, I 00 mg orally, 
again in a double-blind fashion, two days after haemodialysis, when they were fluid 
replete. The effect of captopril on blood pressure was followed for two hours until the 
next dialysis session was started. Finally, captopril, I 00 mg orally. was given on a 
third occasion one day after haemodialysis, and its effect was assessed after 24 hours. 
just before the next dialys}s session was started. 
Enzymatically active plasma renin was measured by radioimmunoassay of angioten-
sin I which was generated after incubation for three hours at 37°C and pH 7.5 with an 
excess of purified sheep renin substrate (14). Results were expressed as I'U of an 
international renin standard (MRC 68/356). The normal value in our laboratory is 
15-40 I'U/ml. The converting enzyme activity of plasma was measured by the rate of 
production of hippuric acid from hippuryl-L-histidyl-L-leucine (15) and expressed as 
a percentage of the control value before captopril. 
For statistical comparison of data we used Student's paired !-test. P values less than 
0.05 were considered to indicate statistically significant differences. 
-58-
TABLE 1: EFFECT OF CAPTOPRIL 100 MG ORALLY OR PLACEBO ON 
ACTIVE PLASMA RENIN AND ANGIOTENSIN-CONVERTING 
ENZYME ACTIVITY IN THE FLUID-DEPLETED AND FLUID-
REPLETE STATES. 
I hour after haemodialysis: 
- placebo 0 min 
24 hours 
- Captopril 0 min 
30 min 
60 min 
120 min 
24 hours 
24 hours after haemodia\ysis: 
- Captopril 0 min 
24 hours 
48 hours after haemodialysis: 
- Captopril 0 min 
120 min 
5.4. Results 
Active plasma renin 
p:U/ml) 
1.8±0.5 
1.5±0.3 
1.6±0.4 
1.6±0.5 
1.2±0.5 
1.1 ±0.3 
2.1±0.4 
1.8±0.3 
1.7::::0.5 
1.7±0.3 
1.6±0.4 
Converting enzyme activity 
(%of control value at 0 min) 
100 
99± 6 
100 
49±11 
37±14 
28± 8 
30± 7 
100 
29± 8 
100 
19± 9 
Bodywcight 
(kg) 
56.7±1.6 
57.5±1.6 
56.6± 1.8 
57.3±1.8 
57.4±1.7 
58.5± 1.6 
58.4± 1.6 
In the fluid-depleted state one hour after haemodialysis body weight on captopril was 
not significantly different from that on placebo (see Table). Supine blood pressure on 
placebo, which was given one hour after dialysis) did not change over a period of two 
hours, and after 24 hours it had significantly increased (p<O.OI; Fig. 1). In contrast, 
supine blood pressure fell with captopril and, 30-120 minutes after the drug had been 
given, blood pressure was significantly lower than on placebo. Two hours after pla-
cebo blood pressure did not change on standing for two minutes, but it fell after 
captopril (p<0.05; Fig. 2). Twentyfour hours after captopril had been given, all 
patients complained of dizziness and had overt orthostatic hypotension. Four of them 
nearly fainted on standing. There was no significant difference in supine heart rate 
between the captopril and placebo periods, and the increments of heart rate on 
standing were also the same (Fig. 2). 
Figs. 3 and 4 compare the effects of captopril on supine and standing blood pressures 
in the fluid-replete state with those after fluid withdrawal. Supine and standing blood 
pressures were higher in the fluid-replete state two days after haemodialysis and blood 
pressure did not fall after captopril. The orthostatic fall in blood pressure induced by 
captopril in the fluid-depleted state was not observed after fluid repletion. The incre-
ments in heart rate on standing were similar before and after captopril in both fluid-
depleted and fluid-replete states. 
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Figure L Effect of captopril versus placebo on blood pressure in seven fluidMdepleted anephric subjects. 
NS=not significant ... =p<O.OS. **=p<O.Ol. ***=p<O.OOI. 
Active plasma renin concentrations were extremely low in all patients and did not 
respond to fluid withdrawal or to captopril (see Table). As judged from measurements 
of converting enzyme activity in plasma, captopril was effective for at least 24 hours 
in our patients. 
5.5. Discussion 
Our findings show that blood pressure can be greatly reduced in anephric subjects by 
captopril, an agent known to inhibit both the formation of angiotensin II and degrada-
tion of bradykinin. Since the main source of renin has been removed and plasma renin 
and angiotensin II concentrations are very low in these patients (16), it is unlikely that 
this effect depends on the circultating levels of these hormones. Blood pressure fell 
after captopril whenever the patients were not overloaded with fluid. A similar 
influence of fluid balance on the hypotensive response to angiotensin-converting 
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Figure 2. Effects of captopril versus placebo on supine and standing blood pressure and heart rate in seven 
fluid·depleted anephric subjects. See legend to Fig. 1 for statistical values. 
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Figure 3. Effect of captopril in fluid-depleted and fluid-replete states on blood pressure in seven anephric 
subjects. See legend to Fig. I for statistical values. 
enzyme inhibitors and angiotensin II antagonists has been ·observed in normotensive 
and hypertensive subjects who have not undergone nephrectomy (I 0-12, 17). This is 
commonly taken as evidence that blood pressure becomes 'renin dependent' when the 
release of renin is stimulated by sodium and water depletion. Our observations in 
anephric subjects, who had very low plasma renin concentrations which did not 
increase after fluid withdrawal, strongly suggest that factors unrelated to circulating 
renin are important for maintaining blood pressure after sodium and water depletion. 
The hypotensive effect of captopril is probably also not related to circulating bradyki-
nin concentrations. Studies with the converting enzyme inhibitor teprotide (SQ 20 
881) in man failed to show any effect on plasma bradykinin values (12, 18). A 
transient rise in plasma bradykinin after teprotide has been reported (19, 20), but the 
bradykinin values in that report were ten times higher than those in a more recent 
study which failed to show significant changes in plasma bradykinin in patients with 
essential hypertension treated with long-term captopril (21). 
Angiotensin-converting enzyme is present in the vascular endothelium (22) and renin 
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Figure 4. Effects of capwpril in fluid-depleted and fluid-replete states on supine and standing blood pressure 
and heart rate in seven anephric subjects. See legend to Fig. 1 for statistical values. 
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has been extracted from the arterial wall (23, 24). A physiological role for vascular 
renin in maintaining blood pressure in the hypertensive anephric rat has been recently 
put forward by Thurston and Swales (25), who found that inhibition of converting 
enzyme resulted in a considerable fall in blood pressure one and two hours after 
nephrectomy, when plasma renin had already declined to insignificantly low values. 
Furthermore, plasma prekallikrein, which circulates as a complex with its substrate, 
high-molecular-weight kininogen, is rapidly absorbed together with factor XII on 
negatively charged surfaces, such as collagen and vascular basement membrane (26). 
This leads to activation of factor XII and the local formation of kallikrein and possibly 
also bradykinin. Captopril may thus act in the blood-vessel wall or in close contact 
with it, rather than in the circulating blood. 
Haemodynamically, captopril acts as a vasodilator with an important effect on the 
veins (27. 28). Venous dilatation will tend to reduce venous return to the heart and 
consequently cardiac output. This might explain why captopril caused orthostatic 
hypotension in our anephric patients when they were fluid depleted. It may be rele-
vant that the rare syndrome of familial hyperbradykininism is characterised clinically 
by severe orthostatic hypotension (29). The enhancement of captopril's hypotensive 
effect by sodium and water depletion, which has also been observed in subjects who 
have not undergone nephrectomy, might be an indication of the importance of blood 
volume rather than plasma renin for maintaining blood pressure. Hypotension will not 
develop as long as 'effective· blood volume and cardiac filling pressures are adequate. 
The alleged transition of so-called 'volume-dependent' hypertension into 'renin-
dependent' hypertension after sodium and water depletion, for instance by diuretics, 
might therefore be an illusion rather than reality. 
Whatever the underlying mechanism of captopril's hypotensive effect, our results lend 
further support to preliminary suggestions that this drug will be effective in the large 
group of hypertensive patients in whom plasma renin is not raised. 
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CHAPTER 6 
Captopril affects blood pressure equally in reno-
vascular and essential hypertension and in the 
fluid-depleted anephric state 
6.1. Summary 
The haemodynamic effects of I 00 mg of captopril in renovascular hypertension 
(n =II). essential hypertension (n = 12) and the anephric state (n=7) were compared. 
Brachial artery pressure was measured in all patients, and changes in right atrial 
pressure, pulmonary artery pressure, pulmonary capillary wedge pressure and cardiac 
output were followed in renovascular and essential hypertension. Nephrectomized 
patients were studied before and after fluid withdrawal by ultrafiltration. 
The pretreatment concentration of active renin in plasma was 100±24MU/ml (mean 
±SEM) in renovascular hypertension. and 24±41-'U/ml in essential hypertension. in 
nephrectomized patients pretreatment renin was 1.7±0.3 ,uU/ml. and renin was 
unresponsive to withdrawal of 1.8±0.2 liters of body fluid. 
The effects of captopril were maximal after 60-90 min. Mean arterial pressure after 90 
minutes was lowered by 19±4% in renovascular hypertension, by 17±4% in essential 
hypertension and by 16±3% in fluid-depleted nephrectomized patients. These chan-
ges were not significantly different despite the marked differences in renin. Captopril 
had no effect on arterial pressure in the fluid-replete anephric state. 
The effects of captopril on cardiac filling pressures and cardiac output in renovascular 
and essential hypertension were also not different. It is concluded that the antihyper-
tensive action of captopril may be largely independent of circulating renin. 
6.2. Introduction 
The orally active angiotensin-converting enzyme inhibitor, captopril (SQ 14 225). has 
now proved to be an effective antihypertensive agent. The drug is thought to act 
mainly or at least partly through interference with the conversion of angiotensin I into 
angiotensin II ( 1.2). It might therefore be expected that captopril would be especially 
effective in hypertensive patients with high levels of circulating renin. 
Several reports. however, suggest that captopril is also effective when plasma renin or 
angiotensin II are normal or low (3-8). Atkinson et al (4). while demonstrating a close 
correlation between the fall in plasma angiotensin II and the fall in blood pressure 
after the initial dose of captopril, emphasized that this does not establish cause and 
effect; factors other than the change in angiotensin II might be involved. In an effort to 
assess the importance of plasma renin as a determinant of the cardiovascular responses 
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to captopril, we have compared the short-term haemodynamic effects of this drug in 
renovascular hypertension. essential hypertension and the anephric state. 
6.3. Patients and methods 
Eleven patients (mean age 47±SEM 5 years) with renovascular hypertension, who 
showed angiographic evidence of unilateral renal artery stenosis, 12 patients (age 
50±3 years) with essential hypertension, and seven normotensive subjects (38±4 
years) who had undergone bilateral nephrectomy. agreed to participate in the study. 
The pretreatment concentration of active renin in plasma was 1 00±24 f.J.U/ml (range 
21-290 I'U/ml) in renovascular hypertension. 24±4 I'U/ml (range 4-68 I'U/ml) in 
essential hypertension and 1.7±0.3 f.LU/ml (range 0.0-3.4 f.LU/ml) in nephrectomized 
patients. The normal range is 15-45 f.LU/ml (10). 
The patients with renovascular and essential hypertension had a diet containing 100 
mmol of sodium/day. and were on placebo for three weeks before captopril was 
given. Studies were performed in the recumbent patient. A catheter was introduced 
into the brachial artery for measuring arterial pressure and for blood sampling. A 
Swan-Ganz flow-directed triple-lumen catheter was introduced via an antecubital 
vein for recording right atrial pressure, pulmonary artery pressure and pulmonary 
capillary wedge pressure, and for measuring cardiac output by thermodilution. All 
patients received a 100 mg tablet of captopril. 
The nephrectomized subjects underwent dialysis three times a week on a Rhodial-75 
single-patient unit with a RP-6 disposable polyacrylonitryl membrane kidney. The 
recirculating dialysate contained 140 mmol of sodium/!. Captopril (100 mg) or pla-
cebo was given in a randomized cross-over study on two occasions: 1) after fluid 
withdrawal by ultrafiltration (weight loss 1.8±0.2 kg), one hour after the patients 
were disconnected from the kidney, and 2) two days after haemodialysis when the 
patients were fluid-replete. The concentration of active renin in plasma was unrespon-
sive to fluid withdrawal. Blood pressure in these subjects was measured by the London 
School of Hygiene sphygmomanometer (II). and mean arterial pressure was calcula-
ted according to the formula: mean arterial pressure =diastolic pressure + 0.33 X 
pulse pressure. 
The effects of captopril were maximal after 60-90 min. Data before and 90 minutes 
after captopril were analysed by paired t-test statistics. 
6.4. Results 
Arterial pressure. Mean arterial pressure fell from 141±6 to 114±6 mm Hg in 
renovascular hypertension, from 136±6 to 114±7 mm Hg in essential hypertension 
and from 90±7 to 75±6 mm Hg in the fluid-depleted nephrectomized patients. These 
changes were significant (p<O.OOl ). Placebo in the fluid-depleted anephric state, and 
captopril in the fluid-replete anephric state, had no effect on arterial pressure. 
Heart rate and cardiac index. In all groups of patients heart rate did not change 
significantly. Cardiac index in renovascular hypertension was 3.5±0.1 llmin before 
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captopril and 3.4±0.2 llmin after the drug. The difference was not statistically 
significant. Cardiac index in essential hypertension was 2.9±0.1 1/min both before 
and after captopril. 
Cardiac filling pressures and pulmonary artery pressure. Right atrial pressure fell 
from 2.6±0.9 to 1.6±0.9 mm Hg (p<0.05) in renovascular hypertension. and from 
0.7±0.8 to -0.8±0.9 mm Hg (p<O.OI) in essential hypertension. Pulmonary artery 
pressure decreased from 16±2 to 13±2 rnm Hg in renovascular hypertension 
(p<O.OI) and from 12±1 to 10±1 mm Hg in essential hypertension (p<O.OI). 
Pulmonary capillary wedge pressure fell from 7.5± 1.1 to 5.2± !.2 mm Hg (p<0.005) 
in renovascular hypertension and from 4.4±0.9 to 1.0±!.0 mm Hg (p<O.OO!) in 
essential hypertension. 
Plasma renin. Active renin in plasma rose both in renovascular and essential hyper-
tension. to 890±1!0 and 1!6±24 ,uU/ml respectively. Renin did not change after 
captopril in the nephrectomized patients. 
In Fig. l the percentage changes in mean arterial pressure 90 minutes after captopril as 
well as the pretreatment plasma levels of active renin are compared in the three groups 
of patients. lt is clear that the effect of captopril on blood pressure was unrelated to 
pretreatment renin values. 
6.5. Discussion 
In the light of our present knowledge on captoprirs mode of action, one would expect 
its effect on blood pressure to be proportional to the pretreatment level of plasma 
renin. Such a correlation has indeed been found by some authors (I, 6. 8, 12) but not 
by others (3, 5, 7). The correlation, if it was found, was rather weak or depended on 
inclusion of data obtained in patients with high plasma renin on low sodiur. diet or 
diuretics. In the present study the antihypertensive effect of captopril was similar in 
renovascular and essential hypertension despite the marked differences in pretreat-
ment plasma renin. 
Our haemodynamic studies confirm that captopril acts as a combined arterial and 
venous dilator (13-15), which in contrast to other vasodilators. does not lead to reflex 
tachycardia. Again, the effects of captopril on systemic and pulmonary haemody-
narnics were not different in our groups with renovascular and essential hypertension 
despite the difference in renin. 
Diuretic treatment is kown to enhance captopril's anti-hypertensive effect (I, 6, 7), 
and in severe sodium depletion serious hypotensive responses have been observed (1, 
9). This is often used as an argument in favour of the concept that captopril acts 
through inhibition of renin-mediated angiotensin n formation, because plasma renin 
is markedly increased by sodium and fluid depletion. It is, however, by no means 
certain that the increase in renin is the cause of the augmented blood pressure response 
to captopril. Actually, we found that captopril was capable oflowering blood pressure 
in anephric subjects only when they were fluid-depleted, whereas plasma renin after 
fluid depletion was as low as in the fluid-replete state. Blood pressure in the fluid-
depleted anephric subjects was lowered by 16% 90 minutes after captopril. and this is 
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Figure I. Pretreatment plasma renin (mean±SEM) and the percentage changes in mean arterial pressure 90 
min after 100 mg of captopril in renovascular hypertension (RVHT). essential hypertension (EHT) and in 
the anephric state (Nx)- *After ultrafiltration; ubefore ultrafiltration. 
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comparable with the effects we observed in renovascular and essential hypertension 
(Fig. I). 
These findings suggest that the antihypertensive action of captopril is largely indepen-
dent of circulating renin. 
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CHAPTER 7 
Opposite effects of captopril on angiotensin!-
converting enzyme 'activity' and 'concentration'; 
relation between enzyme inhibition and long-
term blood pressure response 
7.1. Summary 
The relationship between the antihypertensive action- of captopril and its inhibitory 
effect on angiotensin I (ANG I)-converting enzyme h:is been investigated. Converting 
enzyme was measured in plasma by its ability to generate hippuric acid from the 
synthetic substrate hippuryl-L-histidyl-L-leucine. Inhibition by captopril appeared 
transient on storage of the plasma samples at -20°C, so that measurements in such 
samples were not a valid index of the effect in vivo. 
Rapid reversal of captoprirs inhibitory effect on ANG !-converting enzyme in plasma 
was achieved by the addition of N-ethylmaleimide (0.1 mmol!l). In this way an 
estimate of converting enzyme 'concentration' was obtained both in stored and in 
freshly prepared samples. Measurements of converting enzyme 'activity" in freshly 
prepared samples in the absence of N-ethylmaleimide, were used as an index of 
inhibition in vivo. 
In eight hypertensive subjects ANG !-converting enzyme 'concentration' did not 
change after a single oral l 00 mg dose of captopril. Long-term treatment of 10 
hypertensive subjects with captopril was associated with a gradual increase in conver-
ting enzyme 'concentration' from 29±2 to 47±3 I'U/ml (mean±SEM) over a period 
of several weeks. In contrast, captopril caused a rapid fall of converting enzyme 
'activity'. Abrupt withdrawal of captopril after long-term treatment caused a gradual 
decrease in ANG !-converting enzyme 'concentration' to the control value. In cont-
rast, converting enzyme 'activity' rose rapidly and became equal to enzyme 'concent-
ration' two days after the drug had been stopped. 
The concentration of enzymatically active renin in plasma rose from 13±3 to 81 ±34 
I'U/ml during long-term captopril treatment (mean±SEM). Blood pressure fell from 
168±4/ 108±3 to 140±3190±3 mm Hg and had not returned to the control value in 
the first week after the drug had been stopped, despite the fact that circulating active 
renin and ANG !-converting enzyme 'activity' were elevated. 
It is concluded that long-term inhibition of ANG !-converting enzyme by captopril is 
associated with an increased plasma concentration of this enzyme. The results also 
suggest that the level of converting enzyme 'activity' in plasma is not the only factor 
that determines the long-term effect of captopril on blood pressure. 
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7 .2. Introduction 
Captopril is now being evaluated as a promising drug for the treatment of various 
forms of hypertension. lt is generally assumed that captopril's action on blood pres-
sure is closely linked to its inhibitory effect on ANG !-converting enzyme ( 1. 2). More 
recently) however. some discrepancy between measured ANG !-converting enzyme in 
plasma and the response of blood pressure has been reported (3.). During the course 
of a study designed to collect data to clarify this point, we measured variable decre-
ments of ANG !-converting enzyme in plasma of patients on captopril on storage of 
the samples at -20°C. This was not the case in plasma taken from subjects who were 
not on captopril. These findings suggested to us that inhibition of ANG !-converting 
enzyme by this drug was partly reversed after storage of plasma at -20°C, so that 
measurements of ANG !-converting enzyme in stored samples are not a valid index of 
inhibition in vivo. 
We have. therefore. developed a method in vitro by which a reproducible and almost 
complete reversal of the inhibitory effect of captopril can be attained. This enabled us 
to measure ANG !-converting enzyme "concentration" and to compare this with mea-
surements of ANG !-converting enzyme 'activity'. The term 'concentration' is used 
here to designate the total concentration of circulating enzyme, i.e. the sum of inhibi-
ted and uninhibited enzyme. The term ·activity' refers to circulating uninhibited 
enzyme only. The results to be presented here indicate that ANG !-converting enzyme 
'concentration· increases with long-term inhibition of the enzyme by captopril. 
7.3. Methods and patients 
Assay of ANG !-converting enzyme 
Procedure. ANG !~converting enzyme in plasma was measured by a spectrophoto-
metric assay based on the methods of Cushman and Cheung ( 4) and Le Treut et al 
(5). Peripheral venous blood was collected into tubes containing lithium heparin as 
anticoagulant. Plasma was prepared by centrifugation at4°C, immediately after blood 
sampling. A 50 Ml portion of plasma was added to ::wo Ml of a freshly prepared 
solution of the substrate hippuryl-L-histidyl-L-leucine (from Sigma Chemical Co.) in 
borate/NaCl C'lffer. The substrate solution contained the following components at the 
final concentrations indicated: hippuryl-L-histidyl-L-leucine (5 mmolll), sodium 
borate (0.1 moll!) and NaCl (0.3 moll!); pH was adjusted to 8.3. The substrate/pla-
sma mi~ture was incubated at 37°C in a shaking water bath for 1 h. The reaction was 
stopped with 250 Ml of HCI (! moll!). A blank was prepared by adding the acid 
before the incubation. Hippuric acid that was formed during incubation was extracted 
with 1.5 ml of ethylacetate by mixing on a vortex mixer (15 s). After centrifugation l 
ml of the organic layer was transferred to a new tube. The ethylacetate was evaporated 
and 2 ml of NaCl solution (l moll!) was added, followed, after mixing, by 2 ml of 
light petroleum (boiling point 40-60°C). The tubes were then vortexed (15 s) and 
after centrifugation the light petroleum layer was removed by aspiration. The absor-
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bance at 228 nm was read in a l em quartz cuvette. The absorbance of the blank was 
substracted from the absorbance of the corresponding test sample. 
Results of ANG !~converting enzyme measurements are expressed in milli-units per 
millilitre of plasma (m-units/ml), I unit being the quantity of enzyme that produces I 
I' mol of hippuric acid/min. The production of hippuric acid from hippuryl-L-histidyl-
L-leucine was linear with respect to time for at least 1 hour and dilution experiments 
(Fig. I) ascertained the linearity of the assay for ANG !-converting enzyme levels up 
to 80 m-units/ml. Samples were assayed in duplicate. Both intra- and inter-assay 
variabilities were <5%. 
As described above, the incubation of plasma with substrate was carried out in sodium 
borate buffer of pH 8.3. In the original methods of Cushman and Cheung ( 4) and Le 
Treut et al (5) potassium phosphate buffer of the same pH was used. We found, 
however. that with the use of potassium phosphate at concentrations of 0.1 and 0.25 
moll! measured ANG !-converting enzyme was reduced by 35 and 65% respectively 
as compared with values in borate buffer. 
Specificity and linearity of the assay. The cleavage of the synthetic substrate by plasma 
could be reduced to undetectable levels by the addition of the ANG !-converting 
enzyme inhibitor. captopril. to the incubation medium (see below). Thus peptidases 
that are not inhibited by captopril are not detected by the assay, thereby indicating 
that the reaction is mainly, if not only. dependent on ANG I-converting enzyme. 
Several workers ondertook the purification of ANG !-converting enzyme from tissue 
and plasma and found corresponding estimates of purity with the natural substrate 
ANG I and with synthetic substrates (6.7). This again is an indication of the specificity 
of the synthetic substrate. Moreover. a dose linear correlation was found between the 
rate of cleavage of the· synthetic substrate and the concentration of partly purified 
enzyme. 
To confirm the validity of the assay procedure various dilutions of plasma from a 
hypertensive patient were added to (a) NaCl solution (0.15 molll). (b) plasma from 
the same patient five days after a 12-week course of captopril treatment ( 450 mg/day, 
orally) had been completed, and (c) plasma from a patient with sarcoidosis. ANG 
!-converting enzyme was measured as described before. The straight lines shown in 
Fig. 1 strongly suggest that a higher rate of cleavage of the synthetic substrate corre-
sponds to a greater amount of enzyme. 
Distinction between ANG /-converting enzyme 'concentration' and ANG !-converting 
enzyme 'activity' by the use of N-ethylmaleimide. 
When captopril is not present in plasma, the rate of hippuric acid production from the 
synthetic substrate hippuryl-L-histidyl-L-leucine can be used as an estimate of the 
concentration of ANG !-converting enzyme. In the presence of captopril, however, 
the reaction velocity depends on that portion of the total quantity of enzyme that is 
not inhibited by captopril. 
The inhibition of ANG !-converting enzyme by captopril, which contains a functional 
thiol group, can be reversed by adding N-ethylmaleimide to the incubation mixture of 
the assay. N-ethylmaleimide reacts with captopril to form a stable derivative. which 
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Figure i. Linearity of ANG I-converting enzyme measurement in various dilutions of plasma. Diluted 
plasma (30 .ul) from a hypertensive patient was added to 20 f.tl of (a) NaCI solution (0.15 mol/1). (b) 
plasma from the same patient 5 days after completion of a 12-week course of captopril treatment (450 
mg/day, orally). and (c) plasma from a patient with sarcoidosis. Data are the means of five experiments. 
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does not inhibit ANG !-converting enzyme. This process is strongly dependent on the 
concentration of N-ethylmaleimide. Moreover. at high concentrations of this agent an 
increase in absorbance at 228 nm is observed after incubation at 37°C, no matter 
whether converting enzyme and synthetic substrate are present or not. Fig. 2 depicts a 
series of assays in which the influence ofN-ethylmaleimide was assessed. The incuba-
tion was started by adding 50 1'1 of (a) normal plasma. (b) normal plasma containing 
captopril (!0 l'mol/1) or (c) NaCI solution (0.15 mol/l) to 200 1'1 of hippuryl-L-
histidyl-L-leucine in borate buffer and 201'1 of N-ethylmaleimide of various concent-
rations. An incubation ofNaCI solution (0.15 moll!) in borate buffer without synthe-
tic substrate was also carried out (d). In these experiments the concentration of 
captopril in plasma was two times higher than the maximal plasma concentration of 
unchanged captopril in normal volunteer subjects after the oral intake of 100 mg of 
this drug (Squibb, Report no. 1924, 9/74). From these experiments it appears that 
N-ethylmaleimide in concentrations up to 0.1 mmol/1 of incubate does not affect the 
assay of ANG !-converting enzyme and that at a concentration of 0.1 mmol/1 com-
plete reversal of captopril's inhibitory effect is achieved. From Lineweaver-Burk plots 
Km of the reaction of ANG !-converting enzyme with hippuryl-L-histidyl-L-leucine 
was calculated to be 1.56 mmol/1, which agrees with previous reports ( 4,8). The 
addition of N-ethylmaleimide in a final concentration of 0.1 mmol/1 had no 
significant effect on Km or V max. On the basis of these findings we have decided to use 
this concentration of N-ethylmaleimide for measuring the total concentration of con-
verting enzyme, that is the sum of inhibited and uninhibited enzyme, in samples that 
contain captopril. A 20 1'1 portion of a solution containing N-ethylmaleimide (1.35 
mmol/1) and NaCI (0.15 mol/1) was added to the tubes containing the synthetic 
substrate (200 1'1) before the addition of plasma (50 1'1). The addition of 20 1'1 of 
NaCI solution. without N-ethylmaleimide, had no effect on the measured enzyme 
activity. 
In the subsequent analysis we shall refer to ANG !-converting enzyme measured in the 
absence of N-ethylmaleimide as ANG !-converting enzyme 'activity'. We shall refer to 
ANG !-converting enzyme measured in the presence of N-ethylmaleimide as ANG 
!-converting enzyme 'concentration·, because in this way an estimate is obtained of 
the concentration of enzyme irrespective of inhibition of the enzyme by captopril. 
When plasma is free of captopril, the measurements of converting enzyme 'activity' 
and 'concentration" give identical results. 
Assay of enzymalically aclive renin. Active renin in plasma was measured as described 
previously (9, I 0). Plasma was prepared from blood containing disodium 
ethylenediaminetetra-acetate (EDTA, 5 mmol/1). Samples (2 ml) of EDT A-plasma 
were dialysed for 24 hat 4°C against sodium phosphate buffer (disodium hydrogen 
phosphate 86.7 mmol/1, sodium dihydrogen phosphate 12.2 mmol/1 and NaCI 75.9 
mmol/1), pH 7.5, containing EDTA (! mmol/1) and 0.2% neomycin sulphate. Ali-
quots (0.1 or 0.2 ml) of the dialysed samples were diluted with the phosphate buffer 
pH 7.5, to a volume of 0.5 ml and 10 I' I of 8-hydroxyquinoline (0.34 mol/!) and 5 1'1 
of aprotinin (Trasylol, !0000 kallikrein-inhibition units/ml) were added. The mixture 
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figure 2. Influence of N-ethylmateimide on ANG 1-converting enzyme measurements: (a) 50 p.l of normal 
plasma, 200 ,ul of hippuryl-L-histidyl-L-leucine in borate buffer and 20 JJ.l of N-ethylmaleimide ( • ): (b) 50 
f.d of normal plasma containing captopril (IO ,umo\/1), 200 ,u.l of hippuryl-l-histidyl-L-leucine in borate 
buffer and 20 pJ of N-ethylmateimide (A): (c) 50 ,ul of NaCI (0.15 moll!). 200 ,ul ofhippuryl-L-histidyl-L-
leucine in borate buffer and 20 ,u.l of N-ethylmaleimidc (o): (d) 50 ,u.l of NaCI (0.15 moll\), 200 ,ul of 
borate buffer and 20 ,u.l of N-ethylmaleimide (!l). 
was incubated for three hours at 37°C with 0.5 ml of sheep renin-substrate in the 
phosphate buffer described above. The final concentration of substrate in the incuba-
tion mixture was 2.5 ,umol/1, expressed as ANG I equivalents, which corresponds 
with 6.1 X Km. After incubation tli.e mixture was diluted with 1 ml of NaCl solution 
(0.15 moll!), treated for ·10 min in a boiling-water bath and centrifuged. The ANG 
!-concentration of the supernatant was determined by radioimmunoassay. A parallel 
incubation of the same quantities of dialysed plasma and substrate at 4°C served as a 
control. The value of the control was <10% of the value after incubation at 37°C. 
International Reference Standard renin was obtained from the National lnsitute for 
Biological Standards and Control, London. This human kidney preparation (MRC 
standard 68/156) was used as an external standard (!1). Renin concentration is 
expressed as micro-units of this standard per millilitre of plasma (,u U /ml). 
Measurement of blood pressure. The London School of Hygiene sphygmomanometer, 
model MK 4, was used to avoid observer bias and digit preference (12). Blood 
pressure was measured a-fter at least ten min rest, phase V being taken as diastolic 
pressure. 
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Healthy subjects and patients. For studies in vitro blood was taken from 40 healthy 
hospital workers and from ten patien.ts with untreated pulmonary sarcoidosis. The 
effects in vivo of captopril were studied in 18 hypertensive patients. Informed consent 
was obtained in each case. In the hypertensive patients blood pressure was at least 160 
mm Hg systolic and 100 mm Hg diastolic, on two or more occasions when the patients 
were untreated. Routine examinations, including intravenous urography. did not 
reveal any cause of the hypertension in 14 patients. Abnormalities suggesting unilate-
ral renal artery stenosis were found on intravenous urography in four hypertensive 
patients. In each of them the diagnosis was confirmed by arteriography. All drugs had 
been withdrawn for at least six weeks before the studies began. 
Clinical studies. The effects of a single dose of captopril (100 mg. orally) were 
followed in four patients with essential hypertension and four patients in whom the 
hypertension was associated with renal artery stenosis. ANG !-converting enzyme 
'activity' and 'concentration', renin and blood pressure were measured at regular 
intervals after captopril, as indicated in the Results section ("short-term study'). Ten 
patients with essential hypertension were put on long-term treatment with captopril. 
During a first period of treatment the dose of captopril was increased from 25 mg 
three times a day in week one, via 50 and 100 mg three times a day in weeks two and 
three, to 150 mg three times a day in week four. The last dose was continued for nine 
weeks. Captopril treatment was then discontinued and, after four weeks. a second 
course of captopril was given. During this period a fixed dose of captopril. 150 mg 
three times a day. was used for eight months. ANG !-converting enzyme ·activity" and 
'concentration', renin and blood pressure were measured in both treatment periods 
and in the period where treatment was interrupted. Measurements were made at 
regular intervals as indicated in the Results section ('long-term study'). 
Data are presented as mean±SEM. 
7.4 Results 
Experiments in vitro 
Inhibition of ANG !-converting enzyme in plasma by captopril in vitro and the effect of 
storage. Values of ANG !-converting enzyme in plasma of subjects who were not on 
captopril are shown in Table 1. Addition of captopril to this plasma led to inhibition 
of ANG I-converting enzyme. The inhibition was competitive and from Lineweaver-
Burk plots K, was calculated to be 1.9 nmol/1. 
The inhibition was not permanent. but decreased on storage of the plasma at -20°C. 
One day of storage already had an appreciable effect (Table 1). Determinations of 
ANG !-converting enzyme ·activity' in plasma of subjects on captopril are therefore to 
be performed within a few hours after blood sampling. 
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TABLE 1: EFFECTS OF STORAGE AND N-ETHYLMALEIMIDE (0.1 MMOL/1) 
ON ANG !-CONVERTING ENZYME IN PLASMA. 
Source of plasma Handling of plasma before assay ANG l-converting ANG 1-converting 
enzyme (m-units/ml) enzyme (m-units/ml) 
measured in the measured in the 
absence of presence of 
N-ethylmaleimide N-ethylmaleimide 
Patients with Plasma was stored at -20 °C 54.1 ±8.6 57.9±9.5 
sarcoidosis. n =I 0 for 2-6 months 
Patients with essen- Plasma was stored at -20°C 33.3±3.2 30.6±2.1 
tial hypertension, for 2-6 months 
n=l4 
Normal subjects. 
n=IO I) Plasma was stored at -20°C 32.1±2.4 31.3±2.6 
for 2-6 months 
2) Plasma was stored at -20°C 18.3±4.2 27.1±1.8 
for 2-6 months. After thawing 
captopril (0.05 ,umol/ I) was 
added immediately prior to assay 
3) Plasma was stored at -20°C 0 28.1±2.0 
for 2-6 months. After thawing 
captopril (10 ,umol/I) was 
added immediately prior to assay 
4) Captopril (IO Jlmol/1) was I4.4±4.5 28.4±1.5 
added to freshly prepared 
plasma. The samples were then 
stored at -20 °C for 2 weeks 
Normal subjects. I) Plasma was stored on melting 
n=5 ice for <I h: 
- before 25 mg captopril 27.4±2.5 25.9± 1.6 
- I h after 25 mg captopril 3.1±1.0 27.3±2.I 
2) Plasma was stored on melting 
ice for 4 h: 
- before 25 mg captopril 23.7± 1.2 24.4±2.1 
- 1 h after 25 mg captopril 6.4±2.5 24.0±1.9 
3) Plasma was stored at -20 °C 
for I day: 
- before 25 mg captopril 23.2±3.2 26.0± l.4 
- I h after 25 mg captopril 9.8±2.1 26.1 ±1.3 
4) Plasma was stored at -20°C 
for 6 months: 
- before 25 mg captopril 27.6±23 25.8±1.8 
-
1 h after 25 mg captopril 25.7±2.0 26.4±1.8 
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Experiments in vivo 
Short-term study. As shown in Fig. 3, ANG !-converting enzyme 'activity' measured 
in freshly prepared plasma without N-ethylmaleimide fell dramatically. In contrast, 
ANG !-converting enzyme 'concentration' measured in plasma with N-ethyl-
maleimide remained unchanged. After two hours renin had increased from 58± 17 to 
577±127 I'U/ml and blood pressure had fallen from 215±!0/115±5 to 
171 ± 17 /93±7 mm Hg. The effects on ANG !-converting enzyme 'activity', renin 
and blood pressure were maximal at that time. Thereafter, these parameters graduaiiy 
returned to the control values. 
Long-term study. During the long-term treatment with captopril the measurements of 
ANG !-converting enzyme 'activity' and 'concentration'. renin and blood pressure 
were made two hours after the last dose of captopril. ANG !-converting enzyme 
'activity' as measured in freshly prepared plasma was 30±2 m-units/ml before treat-
ment with captopril and 3±2 m-units/ml when the patients were on captopril for 12 
weeks. It rose sharply after discontinuation of captopril treatment and after two days 
without captopril it had reached a value of 42±3 m-units/ml, which is higher than 
that before captopril. In the second course of captopril treatment ANG !-converting 
enzyme 'activity' was 6±3 m-units/ml, which is not different from the value during 
the first course. ANG !-converting enzyme 'concentration· as measured in the pre-
sence of N-ethylmaleimide, rose markedly after captopril. It was 29±2 m-units/ml 
before captopril and 47±3 when the patient was on captopril for 12 weeks. The effect 
of captopril intake on ANG !-converting enzyme 'activity' was observed within 30 
min. The effect on ANG !-converting enzyme 'concentration', however, evolved over 
a period of two weeks. Also the return of ANG !-converting enzyme 'concentration' to 
normal after captopril had been withdrawn took several weeks. At the end of the first 
treatment period, which lasted for 12 weeks, ANG !-converting enzyme 'concentra-
tion' had the same high level as at the end of the second period, which lasted for eight 
months (Fig. 4). Thus the increase in ANG !-converting enzyme 'concentration' 
appears to le""vel off with prolonged treatment, thereby reaching a new elevated pla-
teau. Two days after discontinuation of captopril treatment the difference between 
ANG !-converting enzyme 'activity' and 'concentration' had disappeared. The antihy-
pertensive effect of captopril, however, was still evident at that time despite elevated 
pl2sma levels of ANG !-converting enzyme 'activity' and active renin. 
7 .5. Discussion 
Values for ANG !-converting enzyme in normal plasma observed here are somewhat 
higher than those reported by some authors using the same substrate, i.e.: 22.8 (13) 
22.5 (14) and 20.2 m-units/ml (5). Our values are, however, similar to those reported 
by Friedland and Silverstein: 32.3 m-units/ml (8). The finding that ANG !-converting 
enzyme was increased in pulmonary sarcoidosis is in agreement with the experience of 
Lieberman (!3) and many others (15). 
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Figure 3. Effects of a single 100 mg dose of captopril on arterial pressure. plasma renin and ANG I-
converting enzyme ·concentration· (o) and ·activity' ( ~ ). Results are presented as means±SEM. · 
The results of the present study show that measurements of ANG !-converting enzyme 
in plasJ?la of patients on captopril can not be used as an index of the inhibition of 
circulating t..cuverting enzyme in-vivo, when the samples have been stored at -20°C. 
The inhibition is partly reversed on storage and the degree of deinhibition is variable. 
A similar observation has been made by Roulston and MacGregor (16). The effect of 
storage on ANG !~converting enzyme inhibition is possibly related to changes in the 
reactive thiol group of captopril, probably by oxidation to disulphides (17). As the 
thiol group is important for captopril's inhibitory effect (18), we speculated that 
N-ethylmaleimide, by its reaction with this thiol group, would inactivate the drug. 
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Figure 4. Effects of two courses of long-term captopril treatment on arterial pressure. plasma renin and 
ANG !-converting enzyme 'concentration' ( o) and 'activity" ( • ). Results are presented as means±SEM. 
Indeed the inhibition of ANG !-converting enzyme by captopril was completely 
reversed by N-ethylmaleimide. Measurements of converting enzyme in the presence of 
N-ethylmaleimide can therefore be used as an estimate of the total concentration of 
ANG !-converting enzyme, i.e. the sum of inhibited and uninhibited enzyme. Such 
measurements showed a gradual rise in converting enzyme 'concentration·· after repea-
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ted doses of captopril over a period of weeks. After withdrawal of captopril, ANG 
!-converting enzyme 'concentration' in plasma returned to normal, again over a 
period of weeks. 
The slow response of converting enzyme 'concentration' contrasted with the rapid 
changes in converting enzyme 'activity" as measured in the absence of N-
ethylmaleimide in freshly prepared plasma. The mechanism underlying the increase in 
circulating ANG !-converting enzyme 'concentration' by captopril is not known, but 
it is tempting to consider this an adaptive response to enzyme inhibition. 
Waeber et al (3) have reported that the administration of 200 mg of captopril twice 
daily had an antihypertensive effect, despite their finding that ANG !-converting 
enzyme in plasma was normal for some part of the day. However, their measurements 
of converting enzyme were probably made in stored samples, and, as we have pointed 
out. such measurements underestimate the inhibition of this enzyme in plasma in vivo. 
Nevertheless their conclusion that the effect of captopril on blood pressure and ANG 
!-converting enzyme do not run in parallel is supported by our data. No rebound 
hypertension was observed in our study after abrupt withdrawal oflong-term captop-
ril treatment. On the contrary, blood pressure remained low for some time despite the 
fact that both circulating active renin and ANG !-converting enzyme 'activity" were 
elevated. It appears. therefore, that the level of converting enzyme 'activity' in the 
circulation is not the only determinant of the long-term effect of captopril on blood 
pressure. 
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CHAPTER 8 
Split renal function after captopril m unilateral 
renal artery stenosis 
8.1. Summary 
The renal extraction ratios of 1311-sodium iodohippurate (1 3 '1-Hippuran) and t25I-
thalamate were greatly reduced on the affected side by 50 mg captopril in seven out of 
14 patients with unilateral renal artery stenosis. With long-term captopril 150 mg 
daily the uptake of 99mTc-diethylenetriaminepenta-acetic acid by the affected kidney. 
which was determined by scintillation camera renography, became almost zero in 
these seven patients. indicating severe reduction of the glomerular filtration rate. 
Function of the affected kidney returned on discontinuing treatment. The reduced 
extraction of sodium iodohippurate probably reflected a shortened plasma transit time 
through the kidney due to intrarenal vasodilatation. The reduced extraction of thala-
mate reflected a low filtration fraction, suggesting that the vasodilatation was, at least 
in part. at the level of the postglomerular arterioles. Captopril had little effect on the 
contralateral kidney and on the kidneys of 17 patients with essential hypertension. 
and serum creatinine concentrations showed minor changes. 
Radioisotope renography should be performed after beginning captopril treatment in 
patients with renal artery stenosis. This is also recommended for patients given cap-
topril as a .third line drug when renal artery stenosis has not been excluded. Hyperten-
sion in these patients is often severe and difficult to control. Renal artery disease is not 
rare in this difficult group and finding seriously impaired renal funtion on one side 
during captopril treatment may be diagnostic. 
8.2. Introduction 
Captopril is now widely used for severe hypertension. including that associated with 
renal artery stenosis (1-4). Renal failure, however, may occur in patients receiving 
captopril who have bilateral renal artery stenosis or a stenosis affecting a solitary 
functioning kidney (5-10). Increase in systemic arterial pressure, dilatation ofpreglo-
merular arterioles, postglomerular vasoconstriction, and possibly other mechanisms 
may help to maintain glomerular filtration when renal perfusio-n is compromised by 
artery stenosis (ll, 12). Some of these mechanisms depend, at least in part, on an 
intact renin-angiotensin system. Converting enzyme inhibition, by interfering with 
angiotensin II formation. has therefore the potential to disturb the fine balance 
between pressure and flow required for optimal regulation of glomerular filtration in 
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renal artery disease. In unilateral disease such an effect may easily go unnoticed 
because of the functional reserve of the opposite kidney. 
We report on the effects of captopril on split renal function in these patients. 
8.3. Patients and methods 
Thirty-one hypertensive patients were selected from a larger series of consecutive 
patients because they were shown to have unilateral renal artery stenosis on renal 
arteriography (n= 14; Table I) or because their renal arteries were found to be normal 
on both sides (n= 17). The patients were admitted to this hospital for a diagnostic 
work up because their hypertension was difficult to control; they remained hyperten-
sive despite combined treatment with high doses of diuretics. beta-blockers. hydrala-
zine, and in some cases also methyldopa. Results of urine analysis, serum electrolyte, 
urea, and creatinine concentrations, and urinary excretion of vanillylmandelic acid 
were normal. Medication had been stopped for at least two weeks before renal func-
tion studies and renal vein catheterisation. The renal arteriogram was made after renal 
vein sampling in the same session. 
"
11-Sodium iodohippurate (1 311-Hippuran) and 1251-thalamate were administered by 
constant infusion into an arm vein. After reaching the steady state blood samples were 
taken simultaneously from the abdominal aorta and the renal vein. Samples from the 
same sites were used for renin measurements. The extraction ratio of 131 1-sodium 
iodohippurate (EH) and of 1251-thalamate (ET) and the aortic and renal vein plasma 
renin values were measured 10-15 minutes before captopril and 30-45 minutes after 
50 mg of this drug. Blood samples were also taken at 15 minutes intervals from a 
peripheral vein for estimating total renal clearance of sodium iodohippurate and 
thalamate ( 13. 14). All blood samples were centrifuged immediately and radioactivity 
measured in plasma. Single-kidney extraction ratio (extraction efficiency) was calcu-
lated as (A-V)/ A X !00%. where A=activity in abdominal aorta and V=activity in 
renal vein. The clearance of sodium iodohippurate was taken as a measure of total 
effective renal plasma flow. and the clearance of thalamate was taken as a measure of 
total glomerular filtration rate. 
The single kidney uptake of 99mTc-diethylenetriaminepenta-acetic acid c''mTc-DTPA) 
was determined by scintillation camera renography (15). Approximately 5-!0 mCi 
99mTc-DTPA was injected intravenously. Lightpen 'regions of interest' corresponding 
to the left and right kidneys were traced on the display screen using the three minute 
summation image. Time activity curves of each kidney region were displayed. Coun-
ting rates from the kidney areas were corrected for background activity using a region 
of interest between the kidneys. Single kidney function was estimated from the 
radioactivity over the kidney regions 60-120 seconds after injection and expressed as 
activity ratio, that is, right/(right+left). This ratio is a measure of the single kidney's 
contribution to total glomerular filtration rate (16). The kidney scans were made 
before treatment and after three to five weeks of captoprill50 mg daily. 
The concentration of active renin in plasma was measured by radioimmunoassay (17). 
Blood pressure was measured intra-arterially in the acute study during renal vein 
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TABLE 1: CLINICAL DATA ON PATIENTS WITH UNILATERAL RENAL 
ARTERY STENOSIS. 
Case Age Sex Cause of renal Plasma Renal vein-to-artery 
artery stenosis renin renin ratio 
No years mlf A IF* ,u.U/mJ+ affected contralateral 
47 m A ?" _oo 5.97 0.92 
2 57 m A 6I 3.29 1.02 
3 56 m A 37 2.42 0.94 
4 64 m A 38 I .58 l.12 
5 47 m A 37 L7l 1.17 
6 31 F 23 2.65 0.88 
7 57 m A 480 1.39 0.91 
8 68 A 178 5.81 0.89 
9 57 m A 353 2.09 0.81 
10 58 m A 75 3.08 1.03 
II 65 m A 208 2.20 !.40 
12 25 F 34 1.53 L04 
13 68 m A 40 1.36 !.55 
I4 50 A 42 2.17 0.96 
A=atherosclerosis. F=Fibromuscular hyperplasia. 
+ Normal range: 5-45 ,u.U/ml. 
catheterisation and indirectly with the London School of Hygiene sphygmomanome-
ter in the long-term study. 
Grouped data are presented as means (SEM in parentheses), and differences were 
analysed for statistical significance by Student's t-tests for paired and unpaired data. 
8.4. Results 
Values ofEH and ET were significantly decreased after captopril on both sides both in 
patients with unilateral renal artery stenosis and in essential hypertension (Table II; 
Fig. 1). The effects of captopril on kidneys with a stenotic artery were much greater 
than on kidneys with normal arteries. The renal extraction ratio of a substance equals 
its renal clearance divided by the renal plasma flow. Thus ET=clearance of thalama-
te/true renal plasma flow, or glomerular filtration rate/true renal plasma flow, that is. 
filtration fraction. Our results therefore indicate that the single kidney filtration was 
lowered by captopril, particularly when the kidney was affected by renal artery 
stenosis. 
Since the clearance of sodium iodohippurate did not change after captopril (Table II; 
Fig. 2) and EH=clearance of sodium iodohippurate/true renal plasma flow, the 
observed reduction of EH after captopril implies that true renal plasma flow and 
therefore the total renal blood flow was increased. 
As shown in figure 3, 99mTc-DTPA uptake by the affected kidney became almost zero 
after captopril in seven patients with unilateral renal artery stenosis (group 1) and was 
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Figure I. Effect of 50 mg captopril on renal extraction efficiencies of 13 1I·sodium iodohippurate (EH) and 
1 ~ 51-thalamate (ET) in 14 patients with unilateral renal artery stenosis and 17 patients with essential 
hypertension. In patients with renal artery stenosis changes in EH and ET were significant on both sides 
(p<O.Ol). Changes in essential hypertension were also significant (p<O.OS). 
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TABLE 2: ACUTE EFFECTS OF CAPTOPRIL IN PATIENTS WITH UNI-
LATERAL RENAL ARTERY STENOSIS. GROUP I v GROUP 2. 
GROUP I (n=7) GROUP 2 (n=7) p·Values for difference 
(cases l-7) (cases 8-14) between group I and 2 
before after before after before after 
captopril captopril captopril captopril captopril captopril 
Mean arterial pressure mm Hg 139±5 I 14± 4'*** 137±10 110±10"'* NS NS 
Total effective renal 
plasma flow mllmin 333±35 343±42 320±46 328±48 NS NS 
Total glomerular 
filtration rate mllmin 95±6 82~ 7" 87±8 81± 7' NS NS 
Single-kidney - affected kidney 60±7 29± 7*** 64±5 53:': g• NS <0.001 
extraction ratio 
of hippuran (%) 
- contralat kidney 75::3 71"' 3 74:t3 70± 5 NS NS 
Single-kidney - affected kidney 18±1 6± I*** !7±2 13:'.:: 3'' NS <0.001 
extraction ratio 
thalamatc (%) 
- contralat kidney 24::2 22±3 22± 2 19± 3 NS NS 
values are means± SEM 
* =p<0.05 for difference from the pre-captopril value. .. =p<O.OI. "'** =p<O.OOL 
essentially unchanged in the remaining seven patients with renal artery stenosis (group 
2). It was also unchanged in the patients with essential hypertension. Reductions in EH 
and ET after the first dose of 50 mg captopril were greater in group 1 than in group 2 
(Table II). Serum creatinine concentration rose significantly during long-term captop-
ril in gro.up I but not in group 2 (Table Ill). Neither the changes in blood pressure nor 
the pressure levels that were reached after captopril were, however, different in the 
two groups. None of the patients developed troublesome proteinuria. 
The loss of renal function after captopril in group I appeared not to be due to 
irreversible parenchymal damage. In four patients DTPA uptake was restored one to 
two weeks after captopril had been stopped (Fig. 4 gives an example). By that time the 
plasma creatinine concentration had also returned to its original value. The remaining 
three patients were not restudied after discontinuation of captopril treatment, but 
DTPA kidney scans after reconstructive vascular surgery showed improved uptake on 
the affected side. 
8.5. Discussion 
This study shows that in a substantial number of patients with unilateral renal artery 
stenosis the renal extraction ratio of both 131 I-sodium iodohippurate (EH) and 1251-
thalamate (ET) is greatly reduced on the affected side when captopril is given as the 
only drug. The fall in EH may be explained by a shortened plasma transit time through 
-91-
RENAL ARTERY ESSENTIAL 
STENOSIS HYPERTENSION 
mmHg 230 ARTERIAL PRESSURE 
190 Uou~ uuuuuo 1 50 110 
70 
TOTAL EFFECTIVE RENAL PLASMA FLOW 
ml;min 4.!.1(1 r f-!t-Iil l 360 t t--t-+t-H 280 
TOTAL GLO,~\ERULAR FILTRATION RATE 
mit min 110 
100 H ! -t ! I H+f-N 90 80 
PLASMA RENIN 
>JU /ml 1000 T 
100 
10 A CAPTOPRIL SOmg A CAPTOPRIL SOmg 
-15 0 30 60 -15 0 30 60 
TIME (min) 
Figure 2. Effect of 50 mg captopril on total clearances of 131 1-sodium iodohippurate (effective renal plasma 
flow) and 1251-thalamate (glomerular filtration rate) in 14 patients with uni-lateral renal artery stenosis and 
17 patients with essential hypertension. Effect of captopril after 60 minutes was significant for systolic and 
diastolic intra-arterial pressure (p<O.OOl) and for renin (p<O.Ol). 
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Figure 3. Effect of long~term captopril 150 mg daily on blood pressure and single kidney uptake of 
qqmTc~DTPA in 14 patients with unilateral renal artery stenosis and 17 patients with essential hypertension. 
Patiens with renal artery stenosis divided into two groups according to change in DTPA uptake (see table 
III for statistics). Values in patients with essential hypertension presented as means and SEM. Mean arterial 
pressure calculated as diastolic pressure+0.3 x pulse pressure. London School of Hygiene sphygmomano~ 
meter used. Three consecutive readings with patient in recumbent position were averaged. Effect of captop~ 
ril on mean arterial pressure in patients with essential hypertension was not different from effect in two 
groups of patients with renal artery stenosis. 
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TABLE 3: LONG-TERM EFFECTS OF CAPTOPRIL IN PATIENTS WITH UNI-
LATERAL RENAL ARTERY STENOSIS. GROUP I v GROUP 2. 
Mean arterial pressure mm Hg 
Serum creatinine 
Uptake of 
'"'mTc-DTPA by 
affected kidney 
.umol/1 
percent of 
total uptake 
GROUP 1 (n~7) 
(cases l-7) 
before after 
captopril captopril 
143±7 111 ±6*** 
l00±6 122±9** 
34±3 <10 
**-p<O.Ol for difference from the pre-captopril value. 
***=p<O.OOL 
GROUP 2 (n~7) p-Values for difference 
(cases 8-14) between groups 1 and 2 
before after before after 
captopril captopril captopril captopril 
140±8 114± 5"""* NS NS 
113±12 116±12 NS NS 
31±4 30± 4 
the kidney due to intrarenal vasodilatation. This has also been observed with vasodila-
tation induced by other agents (18). ET equals filtration fraction, and the fall in ET 
after captopril may reflect the dilatation of postglomerular arterioles (10). Captopril 
also lowered EH and ET of kidneys with a normal artery but the changes were not as 
great as for kidneys with artery stenosis. In our patients the fact that the decrease in EH 
on both sides was not associated with a decrease in total clearance of sodium iodohip-
purate is further support for vasodilatation in the kidney, probably on the affected as 
well as the non-affected side. Increase in total renal blood flow and decrease in total 
filtration fraction after captopril have been reported in patients with essential hyper-
tension (19). In those studies the clearance of para-aminohippurate was used as an 
estimate of renal plasma flow with the implicit assumption that the renal extraction 
efficiency was high and remained constant. This. however, may be misleading, as 
shown by our results; the effects of captopril on renal blood flow and filtration 
fraction would be grossly underestimated ·in some patients. 
Other significant findings were the changes in the 99mTc-DTPA kidney scans showing 
a decrease in glomerular filtration rate during long-term captopril treatment. This was 
seen only with kidneys affected by artery stenosis. It also appeared to be an all or none 
phenomenon, that is, the uptake of DTPA by the affected kidney became either al-
most zero or showed little change. The deterioration in renal function was observed in 
half of our patients, but this high incidence may have been related to selection; all had 
been referred to us because of severe hypertension that was difficult to control. 
Deterioration of renal function does not occur only with captopril (20), but conceiva-
bly converting enzyme inhibitors may be especially likely to cause this complication. 
Acute converting enzyme inhibition with captopril or angiotensin II blockade with 
saralasin caused renal failure in rats with chronic two kidney, two clip hypertension 
pretreated with frusemide (21). By contrast, the direct smooth muscle relaxants mino-
xidil and dihydralazine did not have this effect, despite a similar fall in systemic 
arterial pressure. Such findings have also been reported in a few patients with bilateral 
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Figure 4. Sequential ""mTc-DTPA kidney scans in patient with unilateral renal artery stenosis (case 3; 
table I) before captopril. after four weekS of captopril 150 mg daily. and one week after stopping captopril. 
Time after radioisotope injection indicated. 
renal artery stenosis or with a stenotic artery to a solitary functioning kidney (7-9). 
Most of these patients had been treated with captopril in combination with other 
drugs, particularly diuretics, More work is needed to establish whether captopril 
either alone or combined with a diuretic is more harmful for the kidney affected by 
artery stenosis than other antihypertensive drugs. 
The effect of captopril on systemic arterial pressure in our patients who responded 
with loss of filtration on the affected side was not greater than in those who maintai-
ned filtration, Thus the degree of reduction in blood pressure is probably .not the only 
factor determining whether or not renal function can be maintained during captopril. 
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Experimental constriction of a renal artery is known to be followed by vasocon-
striction within the affected kidney. and there is good evidence that the postglomeru-
lar vascular resistance is increased so that filtration pressure is restored and glomerular 
filtration rate is maintained. This mechanism is impaired by converting enzyme inhibi-
tion. and filtration pressure may fall, particularly when systemic arterial pressure also 
falls (II. 12). Increased glomerular blood flow after intrarenal vasodilatation may 
partly compensate for this (22). When filtration pressure falls below a critical level. 
however. the kidney stops filtering. It is tempting to assume that this occurred in some 
of our patients. It was the patients with the greatest reductions in EH and ET after 
captopril who responded with loss of filtration. Presumably these were the patients 
with the most severe artery stenosis. An alternative or additional mechanism contribu-
ting to the fall in glomerular filtration rate might be that a critically severe stenosis of a 
large artery becomes more severe after dilatation of the distal vascular bed (23, 24 ). 
This has been reported in renal artery stenosis induced by cuff constrictors in intact 
instrumented dogs (25). 
Fortunately, in none of our patients were the effects of captopril on renal function 
associated with irreversible damage to the renal parenchyma. DTP A uptake was 
restored by discontinuing captopril or after reconstructive vascular surgery. Radioiso-
tope renography should be performed in any patient with renal artery stenosis who is 
taking captopril. Perhaps we should go even further. Until now captopril has been 
used in hypertension mainly as a third line drug when other drugs have failed. Reno-
vascular hypertension is not uncommon in this difficult group. Hence radioisotope 
renography should problably be performed in every patient who has been given 
captopril because of poor response to other drugs when the possibility of renal artery 
stenosis has not been excluded. We believe that finding severely impaired renal func-
tion on one side during captopril treatment calls for withdrawing the drug or perhaps 
lowering the dose. In such cases renal artery stenosis is likely to be the underlying 
disease. 
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CHAPTER 9 
Effects of one year captopril treatment on systemic 
and renal haemodynamics in essential hypertension 
9.1. Summary 
The effects of one-year treatment with the orally active angiotensin-converting 
enzyme inhibitor, captopril) on systemic and renal haemodynamics were compared 
with those of four-week and three-month treatment. The drug was administered at a 
dosage of !50 mg tid and the study was placebo-controlled and comprised nine male 
subjects with uncomplicated essential hypertension. Blood pressure fell from 
162±5/105± I mm Hg on placebo to 138±4/88±1 mm Hg after one year. Heart 
rate and cardiac output were unchanged. Effective renal plasma flow was l 0 percent 
higher than on placebo and both total peripheral and renal vascular resista~ice were 
reduced by about 10 and 20 percent respectively. Glomerular filtration rate was 6% 
higher than on placebo and extracellular fluid volume was reduced by half a litre. 
These changes were not different from the effects observed after four weeks and three 
months, with the exception of glomerular filtration rate. which showed a progressive 
improvement over the one year period. Thus, the short-term cardiovascular effects of 
captopril monotherapy 'are sustained during long-term treatment. Captopril seems to 
have a weak diuretic action and causes a slight improvement of renal function. These 
two effects may contribute to the long-term effectiveness ofthis drug as an antihyper-
tensive agent. 
9.2. Introduction 
In the previous chapters the effects of acute and four-week treatment with captopril 
have been discussed. During such treatment the drug lowers blood pressure mainly by 
arteriolar dilatation possibly combined with some venous dilatation. Captopril did 
not cause the reflex tachycardia and fluid retention that are often seen after treatment 
with other vasodilator drugs. It is uncertain whether these effects of capiopril persist 
with long-term treatment. For instance it has been suggested that in patients with 
moderate hypertension the initial control of blood pressure was lost with long-term 
captopril treatment (I). This chapter describes the systemic and renal haemodynamic 
effects of one-year captopril monotherapy in patients with uncomplicated essential 
hypertension and normal plasma renin. 
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9.3. Patients and study protocol 
Nine male patients (45±3 yr) with mild to moderate essential hypertension were 
treated as outpatients with captopril for one year. After an initial placebo period of 
eight weeks all patients started to take captopril25 mg tid. The concentration of active 
renin in plasma at the end of the placebo period was 19±3 I'U/ml (range 7-36 
I'U/ml). The normal range in subjects on unrestricted sodium intake is 5-45 I'U/ml 
(n=30). After one week the dose of captopril was stepwise increased to 50 mg tid 
during the second week, 100 mg tid during the third week, and ISO mg tid during the 
fourth week. This dose was then continued during the one~year period of observation. 
All measurements were made two to four hours after the last morning dose, when the 
patients had been recumbent for at least one hour. Non-invasive measurements of 
blood pressure, heart rate, cardiac output, extracellular fluid volume, renal plasma 
flow and glomerular filtration rate were made as described in chapter two, at the end 
of the placebo period and after four weeks, three months and one year treatment with 
captopril. In addition, endogenous creatinine clearance was calculated on 24 hour 
urine collections. Sodium intake was not restricted in these patients but it was shown 
to be relatively constant throughout the observation period i.e. 145± 13 mmol/day on 
placebo as compared to 156±14 mmol/day after one year on captopril. 
In one of the patients antinuclear factor, which was negative on placebo, became 
positive after three months of treatment. It was negative again after one year, while 
captopril was continued. No other adverse reactions were seen in these patients. All 
data relevant to body size are corrected to 1.73 m2 standard body surface area. 
Statistical analysis was performed by Student's paired t-test. 
9 .4. Results 
Systemic haemodynamics. Blood pressure fell from 162±5 mm Hg systolic and 
105± 1 mm Hg diastolic on placebo to 138±4 mm Hg systolic and 90±2 mm Hg 
diastolic after four weeks (p<0.001) and to 138±4 mm Hg systolic and 88± 1 mm 
Hg diastolic after one year of captopril treatment (p<O.OOI) (Fig. 1). Heart rate and 
cardiac output did not change. Calculated total peripheral resistance decreased from 
1670±70 dyn s em-' on placebo to 1400±100 dyn s cm-5 after one month (p<O.Ol) 
and to 1480±70 dyn s em_, after one year (p<O.OS). Extracellular fluid volume 
decreased from 14.6±0.3 1 on placebo to 14.0±0.3 1 after four weeks (p<O.OS) and 
to 14.0±0.2 I after one year (p<0.05). 
Renal haemodynamics. Effective renal plasma flow increased from 408±ll ml/min 
on placebo to 455±22 ml/min after four weeks (p<O.OS) and to 445±20 mllmin 
after one year (p<0.05) (Fig. 2). Calculated renal vascular resistance decreased from 
10.1±0.4 dyn s em-' on placebo to 7.8±0.4 dyn s em-s after four weeks (p<O.OOI) 
and to 7.8±0.3 dyn s em-' after one year (p<0.001). Filtration fraction decreased 
from 25.4±0.5% on placebo to 22.8±0.8% after four weeks (p<0.01) and returned to 
pretreatment level after one year, 25.3±0.6%. Glomerular filtration rate had not 
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changed after four weeks but increased from 103±3 ml/min on placebo to !09±3 
mil min after one year (p<0.05). Creatinine clearance increased from I II ±7 mil min 
on placebo to 120±7 mil min after one year (p<0.05). 
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9.5. Discussion 
Our data show that the effects of short-term treatment with captopril on systemic and 
renal haemodynamics are sustained over a period of one year. There was no evidence 
for·the development of tolerance to the drug. As discussed in chapter eight, hippuran 
clearance was not significantly altered in patients with essential hypertension by a 
single gift of 50 mg captopril. However, the renal extraction of hippuran was less 
complete after this drug, indicating a shortening of the renal transit time of hippuran 
due to increased renal plasma flow. It seems likely, therefore that the small increments 
of hippuran clearance observed in the present study are an underestimation of the 
actual effect on renal plasma flow. A modest increase in renal plasma flow after a 
single gift of captopril to a similar group of patients has been reported in the literature 
(2). 
In the present study we observed a small increase in glomerular filtration rate after 
one year of captopril treatment. As described in chapter eight, no significant effect on 
glomerular filtration rate was observed acutely after converting enzyme inhibition, 
although small increments have been reported in the literature (2, 3). Reduction of 
filtration fraction is a common finding in the short-term studies reported so far ( 4, 5), 
and is also observed in the present long-term study. This is compatible with the 
assumption that angiotensin II predominantly acts on the efferent glomerular arterio-
les. Inhibition of converting-enzyme will then lead to a reduction of the post-
glomerular vascular resistance and hence to a reduction of the glomerular filtration 
pressure (6-8). 
Captopril caused a small decrease in extracellular fluid volume suggesting a weak 
diuretic effect. This effect was sustained over the whole one year observation period. 
In conclusion, this stUdy demonstrates that the effects of one year treatment with 
captopril on blood pressure, cardiac output. renal plasma flow and extracellular fluid 
volume-were not different from the effects on these parameters after four weeks of 
treatment. Glomerular filtration rate showed a progressive improvement over the 
one-year period. The reduction of extracellular fluid volume, which suggests a weak 
diuretic effect. together with the slight improvement of renal function may have 
contributed to the sustained antihypertensive effect of captopril. 
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CHAPTER 10 
Summary and conclusions 
10.1. Acute effects of angiotensin·converting enzyme inhibition 
Plasma converting enzyme activity is inhibited by more than 90% from 60 minutes 
upto four hours after a single oral dose of !00 mg of captopril. It gradually returns to 
pretreatment level within 24 hours. Plasma renin rises within 60 minutes after the first 
dose. It also gradually returns to pretreatment level within 24 hours. Blood pressure 
reduction is maximal 60-90 minutes after captopril both in patients with essential 
hypertension and in renovascular hypertension. A similar time course of blood pres-
sure response is observed in patients with chronic heart failure and in fluid-depleted 
nephrectomized subjects. 
The percent changes in blood pressure are not much different in these groups of 
patients despite large differences in the level of plasma renin. In patients with essential 
or renovascular hypertension the reduction of blood pressure is accompanied by a 
decrease in cardiac filling pressures and total peripheral resistance. Cardiac output is 
unchanged in hypertension. In patients with chronic heart failure a more marked 
decrease in cardiac filling pressures is observed, and cardiac output is increased. Heart 
rate is not changed in patients with essential or renovascular hypertension. In chronic 
heart failure, however, heart rate is decreased by captopril. Stroke volume is unchan-
ged in essential or renovascular hypertension but it is increased in chronic heart 
failure. Plasma noradrenaline is not affected by captopril in essential or renovascular 
hypertension (I) but it is suppressed in chronic heart failure (2). 
The profile of captopril's cardiovascular effects is similar to the effects of vasodilator 
drugs that mainly act on arterioles combined with some effect on venules and veins. 
Correlations of the acute changes in blood pressure or total peripheral resistance with 
pretreatment levels of plasma renin can be demonstrated in patients with hypertension 
as well as in chronic heart failure. These correlations, however, are weak and are of 
little importance in clinical practice. Moreover, the correlation between the blood 
pressure response and pretreatment plasma renin is absent with chronic treatment. 
The renal extraction of hippuran is slightly reduced after captopril in patients with 
essential hypertension but it is greatly reduced in renovascular hypertension on the 
side of the kidney affected by artery stenosis. Similar effects can be demonstrated for 
the renal extraction of thalamate. The reduced extraction of hippuran probably 
reflects a shortened plasma transit time through the kidney due to intrarenal vasodila-
tation. The reduced extraction of thalamate reflects a low filtration fraction, sugges-
ting that the vasodilatation occurs, at least in part, at a postglomerular level. The renal 
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clearance of hippuran is not altered but because the renal extraction of hippuran is less 
complete after captopril, the renal plasma flow must be increased. Glomerular filtra-
tion rate is unchanged in most cases except in some patients with renal artery stenosis, 
where sharp reductions in glomerular filtration rate are observed on the affected side. 
We assume that in such cases the filtration pressure has dropped below a certain 
critical level. Unilateral loss of renal function may occur with minor changes of 
plasma creatinine. Although this effect appears to be reversible when captopril is 
withdrawn after a few weeks of treatment. it is possible that irrepairable damage will 
occur after long periods. 
1 0.2. Chronic effects of angiotensin-converting enzyme inhibition 
The concentration of angiotensin-converting enzyme in plasma is increased with 
chronic captopril treatment. Its activity, however, is decreased due to inhibition by 
captopril. The rise in plasma renin that is observed acutely after captopril is sustained 
during chronic treatment. Blood pressure decreases over a period of two to four weeks 
both in patients with essential hypertension and in patients with renovascular hyper-
tension. The acute effect on total peripheral resistance is also sustained during chronic 
treatment. Cardiac output is unchanged in both forms of hypertension. Body fluid 
volumes are not significantly altered in renovascular hypertension but a small sustai-
ned decrease in extracellular fluid volume is observed in essential hypertension. 
The vasodilator effect of captopril on the kidney is also demonstrable during chronic 
treatment. 
When captopril is withdrawn after chronic treatment, the angiotensin-converting 
enzyme activity in plasma increases within two to five days to levels above pretreat-
ment. At that time plasma renin is still elevated, but in spite of this, the blood pressure 
does not rebound and returns gradually to pretreatment values over a period of two 
weeks. In our study, the concentration of uninhibited plus inhibited angiotensin-
converting enzyme in plasma and the degree of inhibition have been measured by a 
chemical assay technique. It has been shown that inhibition df enzyme activity measu-
red in this way in-vitro is an accurate reflection of the inhibition of the conversion of 
circulating angiotensin I in- vivo, as determined by measuring the pressor response to 
intravenously infused angiotensin I. Our results are therefore an indication that bloc-
kade of the circulating renin-angiotensin system is not the only factor that determines 
the chronic effect of captopril on blood pressure. 
Fluid withdrawal enhances the effect of captopril on blood pressure not only in 
hypertensive patients with normal or high circulating renin but also in nephrectomi-
zed patients with virtually no circulating renin. This again suggests that the antihyper-
tensive effect of captopril does not solely depend on its action on the circulating 
renin-angiotensin system. 
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1 0.3. Interpretation of results with respect to captopril's mechanism of action 
Actions that are independent of the circulating renin-angiotensin system. Most of 
circulating angiotensin II originates from angiotensin I-to-II conversion by angio-
tensin-converting enzyme that is located at the luminal surface of endothelial cells 
lining the capillaries, particularly those in the lung. Conversion also occurs in circula-
ting plasma. From our clinical observations we conclude that inhibition of conversion 
at these two sites is not the only mechanism by which captopril exerts its antihyper-
tensive action. Originally captopril was thought to act mainly through blockade of the 
circulating renin-angiotensin system. Our observations, however, indicate that the 
effect on circulating angiotensin II is more important for the acute blood pressure 
response to this drug than for its long-term effect. 
A likely alternative explanation for captopril's antihypertensive effect is inhibition of 
angiotensin-converting enzyme at the tissue level, resulting in diminished local forma-
tion of angiotensin II. Such inhibition has been demonstrated in animals to occur in 
blood vessels, kidney, adrenals and brain (3). Recently the complete renin-angiotensin 
system has been demonstrated in several cell cultures, including neuroblastoma, juxta-
glomerular cells, adrenal cells, endothelial cells and vascular smooth muscle cells 
( 4,5). There is growing evidence that local angiotensin II formation within some 
critical tissues is involved in blood pressure regulation. 
Angiotensin-converting enzyme inhibition or administration of the competitive angio-
tensin II antagonist, sar 1-ala:s-angiotensin It have been demonstrated to lower blood 
pressure in spontaneously hypertensive rats after they have been bilaterally nephrec-
tomized and their circulating renin has dropped to a very low level (6). Converting 
enzyme inhibition also lowers the blood pressure of the two-kidney one-clip renal 
hypertensive rat after removal of both kidneys (7). 
It is interesting to note that the plasma concentration of enzymatically active renin 
was very. low in our nephrectomized patients but that the plasma level of inactive 
renin (prorenin) was much higher. In some patients it is even within the normal range 
(8, 9). One may speculate that prorenin is taken up in the vascular wall and subse-
quently converted into renin. Whereas in the rat the plasma level of renin becomes 
almost zero within 60-90 minutes after bilateral nephrectomy, the level of renin 
decreases more slowly in the aorta (7). The decrease in blood pressure after converting 
enzyme inhibition in nephrectomized animals occurred while aortic renin was still 
present. It has further been reported that in the spontaneously hypertensive rat the 
level of systolic blood pressure is closely correlated with the level of renin in the aorta 
and not with plasma renin (10). 
More direct evidence for the importance of a local vascular renin·angiotensin system 
for blood pressure regulation has recently been provided by experiments in which 
isolated rat hindquarters were perfused with the synthetic tetradecapeptide analog of 
angiotensinogen. At constant flow, perfusion pressure was increased by this analog, 
and this effect was reduced by captopril and by a specific inhibitor of renin (11). 
A third explanation for captopril's blood pressure lowering effect in the presence of 
low plasma renin could be an effect that is not mediated by reduction of angiotensin II 
but by accumulation of bradykinin. Measurements of bradykinin in plasma after 
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captopril have given conflicting results but now most investigators agree that plasma 
bradykinin is not increased by converting enzyme inhibition (12). We have not per-
formed bradykinin measurements in the present study. There are still formidable 
technical difficulties in accurately quantifying low levels of circulating bradykinin. 
Moreover, the kallikrein-kinin system is regarded as a local system, important in 
regulating organ blood flow and vascular resistance, rather than as a circulating 
hormonal system. Circulating levels, therefore, may not reflect increased local tissue 
kinin levels. Indeed, urinary kinins, which arise from intrarenal activity of the 
kallikrein-kinin system have been reported to increase after converting enzyme inhibi-
tion therapy of hypertensive patients (13). Furthermore, bradykinin receptors 
decrease after such treatment suggesting down regulation of these receptors by increa-
sed local kinin concentration. · 
Actions on target organs that are involved in blood pressure regulation. A decrease of 
angiotensin II in the circulation lowers blood pressure because of reduced occupancy 
of postsynaptic vascular angiotensin 11-receptors that mediate vasoconstriction. 
Reduced occupancy of adrenal angiotensin II-receptors with subsequent suppression 
of aldosterone secretion does not contribute to captopril's acute effect on blood 
pressure but may add to its chronic effect. The fall in plasma aldosterone reported by 
others (14, 24) and the small but significant decrease in extracellular fluid volume we 
have observed in our patients with essential hypertension are consistent with such a 
mechanism. The decrease in circulating angiotensin II after captopril may interfere 
with neurogenic vasoconstriction by reducing the occupancy of presynaptic angio-
tensin 11-receptors on sympathetic nerve terminals (15). Captopril is known to pass 
the blood-brain barrier and neurogenic vasoconstriction may therefore also be sup-
pressed by intracerebral converting enzyme inhibition. Studies in isolated blood vessel 
preparations, in isolated rat kidneys, in pithed rats and in spontaneously hypertensive 
rats provided some evidence supporting bot a central effect on sympathetic neuronal 
activity and a peripheral, presynaptic, effect on sympathetic neurotransmission (16). 
In humans, it has been demonstrated that the pressor response to intravenous infusion 
of noradrenaline is reduced by a single oral gift of 50 mg of captopril (17). In our 
hypertensive patients resting supine levels of plasma noradrenaline and the reflex-
mediated increments in heart rate and plasma noradrenaline were not reduced by 
captopril (I) but this does not exclude an effect of this drug on sympathetic neuronal 
activity or neurotransmission. 
If bradykinin metabolism is affected by converting enzyme inhibitors, then this could 
stimulate the production of the vasodilator, natriuretic, prostaglandin, PGE2 (18). 
Indeed, captopril does increase PGE2-production in hypertensive man (19) and by 
isolated renomedullary interstitial cells (20). Accordingly, cycle-oxygenase inhibitors, 
like indomethacin or similar drugs that inhibit prostaglandin synthesis, can antagonize 
the vascular effects of converting enzyme inhibition (21, 22). 
Finally, the split renal function studies we have performed strongly suggest that 
angiotensin II, either circulating or locally formed within the kidney, has an important 
function in maintaining a normal glomerular filtration rate in the presence of renal 
artery stenosis. Interference with this mechanism by converting enzyme inhibitors 
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may induce renal insufficiency in some patients with renovascular hypertension. 
Thus, we are left with an unexpected dilemma. Converting enzyme inhibitor therapy 
has originally been advocated, and rightly so, for those forms of hypertension where 
circulating renin-angiotensin is high (23, 24). Now, it is realized that this therapy is 
equally effective and causes less adverse reactions in essential hypertension, when 
circulating renin-angiotensin is normal or low. 
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HOOFDSTUK II 
Samenvatting en conclusies 
11.1. Doe! van de studie 
Vele jaren heeft men getracht door farmacologische modulatie van het renine-
angiotensine systeem. de betekenis van angiotensine U, bet biologisch actieve eind-
product van dit systeem. voor de pathogenese van verschillende vormen van hyperten-
sie aan te tonen. De hiervoor gebruikte middelen, zeals beta-adrenoceptor 
antagonisten die bet systeem remmen en diuretica die bet systeem stimuleren, hebben 
echter het bezwaar dat zij in het intacte organisme behaive het renine-angiotensine 
systeem ook andere bloeddrukregelende systemen, zeals het sympathische zenuwstel-
seL beinvloeden. Een nieuwe wijze van benadering werd mogelijk door de synthese 
van competitieve angiotensine II antagonisten en door de ontwikkeling van captopril. 
Angiotensine II antagonisten zijn peptide-analogen van angiotensine II. Zij zijn aileen 
werkzaam na intraveneuze toediening en hebben bovendien bet nadeel dat bet partiele 
agonisten zijn. Captopril is een oraal werkzame specifieke remmer van bet enzym dat 
bet biologisch niet-actieve angiotensine I omzet in bet bloeddrukverhogende angio-
tensine II. Remming van dit "converting enzyme" zal, zo mag men verwachten, 
vooral de bloeddruk verlagen bij die patienten, bij wie het renine-angiotensine sys-
teem is gestimuleerd, zoals bijvoorbeeld bij renovasculaire of maligne hypertensie. De 
eerste studies met captopril bij patienten met hypertensie leverden ecbter wat dit 
betreft tegenstrijdige resultaten op. Ook werd een langdurig effect van dit middel op 
de bloeddruk waargenomen, terwijl bepalingen van bet gehalte aan angiotensine-
converting enzyme in plasma leken aan te geven dat de aanvankelijke remming van dit 
enzym reeds was opgeheven. Bij enkele patienten werd aangetoond dat captopril 
werkt als een arterii.~le en veneuze vaatverwijder, maar onduidelijk bleef of de hoogte 
van de plasma reninespiegel v66r captopril enige voorspellende waarde had voor de te 
verwachten haemodynamische effecten. Over de haemodynamische effecten van 
cbronisch captopril gebruik bij verschillende vormen van hypertensie is nog weinig 
bekend. Dit geldt ook voor de invloed van dit middel op de nierfunctie. Hoewel in 
kortdurende studies een verbetering van de nierfunctie werd aangetoond, is ook ver-
slechtering van de nierfunctie na captopril beschreven. 
Ret hier beschreven onderzoek had tot doel na te gaan of de hoogte van bet renine 
gehalte in plasma v66r behandeling met captopril gerelateerd is aan bet effect van dit 
middel op de bloeddruk, zowel na de eerste dosis als bij chronische toediening, en 
vervolgens om de haemodynamische effecten van angiotensine-converting enzyme 
remming bij verschillende vormen van hypertensie nauwkeuriger te bepalen. Hiertoe 
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werden de effecten van captopril bij de behandeling van patienten met zeer sterk 
uiteenlopende spiegels van plasma renine onderzocht: normotensieve anefrische 
patienten, bij wie het plasma vrijwel geen enzymatisch actief renine be valle, patienten 
met essentiele hypertensie met lage tot normale plasmaspiegels van renine, patii!nten 
met renovasculaire hypertensie met normale tot hoge reninespiegels en tenslOtte nor-
motensieve patienten met decompensatio cordis bij wie de reninespiegels soms 
extreem hoog waren. Ook werd getracht enig inzicht te verkrijgen in de relatie tussen 
de mate van remming van angiotensine-converting enzyme en het antihypertensieve 
effect van captopril. Tevens werden de acute en chronische effecten van dit middel op 
de nierfunctie bestudeerd. 
11.2 Acute effecten van angiotensine-converting enzyme remming 
De converting enzyme acitiviteit in plasma is van 60 minuten tot vier uur na 100 mg 
captopril per os voor meer dan 90% geremd, Over een periode van 24 uur wordt 
geleidelijk de uitgangswaarde weer bereikL Plasma renine stijgt binnen 60 minuten na 
de eerste dosis en keen ook geleidelijk binnen 24 uur terug naar de uitgangswaarde. 
De maximale bloeddrukdaling word! 60 tot 90 minuten na toediening van captopril 
bereikt. zowel bij patienten met essentH!le hypertensie als bij patienten met renovascu-
laire hypertensie. V ergelijkbare effecten op de bloeddruk worden gezien bij nierloze 
patienten na ultrafiltratie-haemodialyse en bij patienten met decompensatio cordis. 
Ondanks grote verschillen in plasma renine bij deze groepen patienten is de procen-
tuele bloeddrukdaling niet erg verschillend. 
Bij patienten met essentiele of renovasculaire hypertensie is er naast de bloeddrukda-
ling sprake van daling van de vullingsdrukken van bet hart en neemt de perifere 
vaatweerstand af. Het hartminuutvolume verandert bier niet. Bij patienten met 
decompensatio cordis wordt een sterkere daling van de vullingsdrukken van het hart 
waargenomen en stijgt bet hartminuutvolume. De hartfrequentie verandert niet bij 
patienten met hypertensie maar daalt bij patienten met decompensatio cordis. Het 
slagvolume verandert niet bij hypertensie maar neemt toe bij decompensatio cordis. 
Plasma noradrenaline verandert niet na captopril bij essentiele of renovasculaire 
hypertensie, maar daalt bij patienten met decompensatio cordis. 
Het haemodynamische profiel van captopril lijkt sterk op dat van vaatverwijdende 
stoffen, die hun werking voornamelijk uitoefenen op de arteriolen en daarnaast ook 
enig effect hebben op venulen en venen. 
Er kan een relatie worden aangetoond tussen de acute veranderingen in bloeddruk of 
perifere weerstand na captopril enerzijds en de hoogte van de reninespiegel in plasma 
v66r de behandeling anderzijds, niet aileen bij patienten met hypertensie maar ook bij 
patienten met decompensatio cordis. De correlaties zijn echter zwak en voor de 
praktijk daarom van weinig belang. Verder is tijdens chronische behandeling met 
captopril een dergelijke relatie tussen de verandering in bloeddruk en de reninespiegel 
v66r de behandeling niet aantoonbaar, 
Bij patienten met essentiele hypertensie neemt de fractionele extractie van hippuran 
door de nieren, uitgedrukt als bet percentage van bet aan denier aangeboden hippuran 
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dat wordt uitgescheiden, na captopril enigszins af. Bij patienten met renovasculaire 
hypertensie is er sprake van een veel sterker afname van deze fractionele renale 
extractie van hippuran, althans aan de kant waar de nierarteriestenose zich bevindt. 
Vergelijkbare effecten konden worden aangetoond voor de fractionele renale extractie 
van thalamaat. De afgenomen extractie van hippuran is mogelijk een uiting van een 
versnelde doorstroming van de nier als gevolg van intrarenale vasodilatatie. De 
afname van de thalamaatextractie is bet gevolg van een daling van de filtratiefractie. 
wat de suggestie wekt dat de vasodilatatie, tenminste voor een deel, op postglomeru-
lair niveau plaatsvindt. Omdat de totale renale .klaring van hippuran niet verandert, 
terwijl de fractionele renale extractie van hippuran na captopril afneemt, moet de 
plasma doorstroming in beide nieren gezamenlijk zijn toegenomen. De glomerulaire 
filtratiesnelheid blijft in de meeste gevallen ongewijzigd, behalve bij enkele patienten 
met een nierarteriestenose, bij wie na captopril een zeer sterke afname van de glome-
rulaire filtratiesnelheid aan de kant van de stenose optreedt. Dit ernstige nierfunctie-
verlies kon worden aangetoond met behulp van renografie waarbij radio-actief DTP A 
(diethyl-triamino-penta-azijnzuur) werd gebruikL Het is aannemelijk dat in een derge-
lijk geval de filtratiedruk tot onder een kritische grens is gedaald. Eenzijdig nierfunc-
tieverlies kan optreden ook wanneer de bloeddruk in de grate circulatie weinig daalt. 
Het kreatinine gehalte van plasma stijgt vaak nauwelijks onder deze omstandigheden, 
omdat de gezonde nier de functie van de aangedane nier overneemt. Hoewel dit effect 
reversibel blijkt wanneer captopril na enkele weken wordt gestopt, lijkt het toch niet 
onmogelijk dat bij langdurige behandeling met een converting enzyme remmer onher-
stelbaar verlies van functie van de nier met een stenotische arterie kan optreden. 
11.3 Chronische effecten van angiotensine-converting enzyme remming 
Tijdens de behandeling met captopril neemt de concentratie van angiotensine-
converting enzyme in plasma toe. De activiteit van bet enzym is echter afgenomen als 
gevolg van de remming door captopril. De vrijwel onmiddellijk na de eerste dosis 
captopril optredende stijging van het plasma renine blijft tijdens langdurige toediening 
aanwezig. Zowel bij patienten met essentiele hypertensie als bij patienten met reno-
vasculaire hypertensie daalt de bloeddruk geleidelijk tot dat een minimumwaarde na 
twee tot vier weken is bereikt. De na de eerste dosis waargenomen daling van de 
perifere weerstand blijft ook bij langdurige behandeling gehandhaafd, Het hartmi-
nuutvolume verandert bij beide vormen van hypertensie niet. Bij patienten met reno-
vasculaire hypertensie verandert het extracellulaire vloeistofvolume niet, maar bij 
essentiele hypertensie wordt blijvend een geringe afname hiervan gevonden. 
Het vaatverwijdende effect van captopril in de nier blijft ook bij langdurige behande-
ling aantoonbaar. 
Als captopril na langdurige behandeling wordt gestopt, neemt de activiteit van 
angiotensine-converting enzyme in plasma binnen twee tot vijf dagen toe tot ver 
boven het uitgangsniveau. Hoewel er op dat moment nog steeds sprake is van een 
verhoogd plasma renine treed! er toch geen rebound-hypertensie op, Na bet abrupt 
staken van chronische behandeling met captopril stijgt de bloeddruk in twee weken 
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langzaam naar het uitgangspunt. De toegenomen concentratie van converting enzyme 
in plasma is waarschijnlijk een uiting van toegenomen synthese, mogelijk ter compen-
satie van de enzymremming. 
In bet bier beschreven onderzoek werd de som van de concentraties van geremd en 
ongeremd angiotensine-converting enzyme, alsmede de mate van remming van het 
enzym, gemeten met behulp van een chemische methode. Er is aangetoond dat de zo 
in-vitro gemeten mate van remming van het enzym een goede weergave is van de mate 
van remming van de omzetting van circulerend angiotensine I in-vivo, gemeten aan de 
bloeddrukstijging na intraveneus toegediend angiotensine I. Ooze resultaten moeten 
dan ook betekenen dat remming van bet circulerend renine-angiotensine systeem niet 
bet enige mecbanisme is waardoor captopril de bloeddruk verlaagt. 
Het onttrekken van vocht versterkt bet effect van captopril op de bloeddruk, niet 
alleen bij patienten met hypertensie, bij wie plasma renine v66r behandeling normaal 
of hoog is, maar oak bij nierloze patienten met vrijwel geen enzymatisch actief renine 
in het bloed. Ook dit is een reden om te veronderstellen dat de werking van captopril 
niet alleen afhangt van het effect op het circulerende renine-angiotensine systeem. Het 
is bekend dat v66rbehandeling met een diureticum de bloeddrukverlagende werking 
van captopril kan versterken. Het ligt voor de hand om te veronderstellen dat dit 
berust op de door bet diureticum veroorzaakte stimulatie van het renine-angiotensine 
systeem. Het onderzoek bij nierloze patienten wijst er ecbter op dat verkleining van 
het extracellulaire vloeistofvolume de werking van captopril potentieert, onafhanke-
lijk van bet -renine-angiotensine systeem. 
11.4 Interpretatie van de resultaten met betrekking tot bet werkingsmechanisme 
van captopril 
Effecten die optreden onafhankelijk van het circulerend renine-angiotensine systeem. 
Het meeste angiotensine II in de circulatie wordt gegenereerd door omzetting van 
plasma angiotensine I door converting eJ1zyme, gelocaliseerd in de celmembraan van 
endotbeelcellen van capillairen vooral in de long. Ook in plasma zelf vindt deze 
omzetting plaats. Uit ooze resultaten blijkt dat de bloeddrukverlagende werking van 
captopril niet alleen door remming van converting enzyme op deze plaatsen kan 
worden verklaard. Bij de introductie van captopril werd aangenomen dat de daling 
van circulerend angiotensine II na captopril bet belangrijkste werkingsmechanisme 
van dit middel was. Ooze gegevens wijzen er echter op dat de daling van circulerend 
angiotensine II belangrijker is voor bet acute effect op de bloeddruk dan voor bet 
chroniss:he effect. 
Een andere verklaring voor de bloeddrukverlagende werking van captopril is de 
remming van angiotensine-converting enzyme in de weefsels met als gevolg een 
afname van locale angiotensine II productie. Bij proefdieren is dit aangetoond voor de 
vaatwand, nieren, bijnieren en bersenen. Recent is bescbreven dat alle componenten 
van het renine-angiotensine systeem worden gevonden in bepaalde celkweken. Ook is 
aangetoond dat bij spontaan-hypertensieve ratten, ook nadat de nieren zijn verwijderd 
en plasma renine zeer sterk is gedaald, toediening van een converting enzyme remmer 
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of van een competitieve angiotensine 1I antagonist de bloeddruk verlaagt. Daarnaast 
blijkt converting enzyme remming de bloeddruk te verlagen bij ratten met hypertensie 
ten gevolge van een eenzijdige nierarteriestenose, ook nadat beide nieren zijn verwij~ 
derd. In de rat daalt het gehalte aan renine in plasma binnen 60-90 minuten na 
nefrectomie, terwijl het gehalte aan renine in de aorta veellangzamer afneemt. Bij de 
genefrectomeerde ratten was op het moment van de bloeddrukdaling renine nog 
steeds aantoonbaar in de aorta. Ook is vastgesteld dat de hoogte van de bloeddruk in 
de spontaan-hypertensieve rat wel gecorreleerd is aan het reninegehalte van de aorta, 
maar niet aan de reninespiegel in plasma. In dit verband is het van belang dat de 
plasmaconcentratie van actief renine in onze nierloze patienten zeer laag was, maar 
dat de spiegel van inactief renine (prorenine) veel boger was, soms was deze zelfs in 
het normale bereik. Het is denkbaar dat prorenine in de vaatwand wordt opgenomen 
en vervolgens wordt omgezet in actief renin e. 
De gedachte, dat een lokaal renine-angiotensine systeem belangrijk is voor de bloed-
drukregulatie, vindt verder steun in recente resultaten van experimenten met geiso~ 
leerde geperfundeerde achterpoten van de rat, waarbij de weerstandsverhoging, die 
werd veroorzaakt door perfusie met een synthetisch angiotensinogeen analoog, kon 
worden tegengegaan door toevoeging van een remmer van angiotensine-converting 
enzyme of van een directe remmer van renin e. 
Een derde verklaring voor de bloeddrukverlagende werking van captopril in situaties 
waarin plasma renine laag is zou kunnen liggen in het feit dat deze niet door een 
afname van angiotensine II, maar door een ophoping van bradykinine wordt veroor-
zaakt. Gegevens over veranderingen in de bradykininespiegel in plasma zijn niet 
eensluidend. maar de meeste onderzoekers zijn het er over eens, dat deze na captopril 
niet toeneemt. Trouwens, het kallikreine~kinine systeem wordt over het algemeen 
meer als een locaal werkend dan als een circulerend hormoonsysteem beschouwd. 
Toename van de locale concentratie van kinines in bepaalde weefsels, behoeft dus niet 
te lei den tot stijging van kininespiegels ill plasma. In dit verband is bet van belang dat 
bij patienten met hypertensie werd aangetoond dat de kininespiegels in de urine stegen 
na converting enzyme remming. Ook is het mogelijk dat een locale toename van 
bradykinine na converting enzyme remming leidt tot toename van bet vaatverwij-
dende en natriuretische prostaglandine, PGE2• Dit is zowel bij patienten met hyper-
tensie als in kweken van geisoleerde niermergcellen aangetoond. In deze richting 
wijzen ook waarnemingen dat geneesmiddelen die de protaglandinesyntbese remmen 
de cardiovasculaire effecten van converting enzyme remming ten dele tegen gaan. 
Effecten op organen die bij de regeling van de b/oeddruk zijn betrokken. Een afname 
van angiotensine II in plasma verlaagt de bloeddruk door een lagere bezettingsgraad 
van postsynaptische angiotensine II receptoren in de vaatwand en daardoor vermin~ 
derde vasoconstrictie. Afname van plasma angiotensine II leidt ook tot een vermin~ 
derde bezettingsgraad van angiotensine II receptoren in de bijnierschors en zo tot een 
afname van de secretie van aldosteron. Dit laatste draagt niet bij tot het acute effect 
van captopril op de bloeddruk, maar kan een rol spelen bij het chronische effect, een 
gedachte die gesteund wordt door de door sommige onderzoekers gevonden afname 
van plasma aldosteron en door onze waarneming dat bij patienten met essentiele 
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hypertensie het extracellulaire vloeistofvolume afneemt onder chronische behandeling 
met captopril. 
De afname van circulerend angiotensine II kan de neurogene vasoconstrictie bein-
vloeden door een verminderde bezettingsgraad van presynaptische angiotensine II 
receptoren op sympathische zenuwuiteinden. Captopril passeert de bloed-hersen bar-
riere en afname van neurogene vasoconstrictie kan dus ook door intracerebrale con-
verting enzyme remming worden veroorzaakt. Uit studies met "gepende" ratten en 
met spontaan-hypertensieve ratten en uit proeven met geisoleerde vaatpreparaten en 
rattenieren komen argumenten naar voren zowel voor een centraal effect op de activi-
teit van bet sympathische zenuwstelsel als voor een perifeer, presynaptisch, effect op 
de sympathische prikkeloverdracht. Bij de mens is aangetoond dat een enkele gift van 
50 mg captopril de bloeddrukverhoging na intraveneus toegediend noradrenaline 
vermindert. Bij ooze hypertensiepatienten daalde de plasmaspiegel van noradrenaline 
onder captopril niet en werden ook de reflexmatige stijgingen van de hartfrequentie en 
het plasma noradrenaline bij houdingsverandering niet beinvloed. Dit sluit echter een 
effect van captopril op de activiteit van het sympathische systeem of op de sympathi-
sche prikkeloverdracht niet uit. 
Uit bet door ons verrichte gescheiden nierfunctie onderzoek blijkt dat converting 
enzyme remming leidt tot vaatverwijding in de nier, waarschijnlijk vooral door 
afname van de postglomerulaire weerstand. T evens blijkt dat locaal in de nier 
gevormd angiotensine !I of circulerend angiotensine II een belangrijke functie heeft 
voor bet handhaven van een normale glomerulaire filtratiesnelheid, vooral in een nier 
met een stenotische arterie. Interruptie van dit mechanisme door captopril kan bij 
sommige patienten met een nierarteriestenose tot nierinsufficientie leiden. 
Er is dus sprake van een onverwacht dilemma. Oorspronkelijk zijn de angiotensine-
converting enzyme remmers ontwikkeld voor de behandeling van die vormen van 
hypertensie, waarbij de plasmaspiegels van renine en angiotensine II verhoogd zijn. 
Het betreft hier vaak patienten met een renale hypertensie en een reeds gestoorde 
nierfunctie of patienten met een nierarteriestenose. N u blijkt echter dat behandeling 
met een converting enzyme remmer niet minder effectief en zeker veiliger is bij 
patienten met ongecompliceerde essentiele hypertensie met een normaal of :z:elfs laag 
renine in plasma. 
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